

Stereoselective Syntheses of (*E*)- α,β -Didehydroamino Acid and Peptide Containing Its Residue Utilizing Oxazolidinone Derivative

Miki Kometani, Kohki Ihara, Rumi Kimura, and Hideki Kinoshita*

Division of Material Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma, Kanazawa 920-1192

Received April 17, 2008; E-mail: khideki@p2223.nsk.ne.jp

Reaction of methyl *N*-Boc-*N*-phenoxy-carbonyl-glycinate with various aldehydes afforded the corresponding *cis*-4,5-oxazolidinone derivatives, which were effectively converted to (*E*)- α,β -didehydroamino acids by means of a base. Furthermore, N-deprotection of the oxazolidinone derivatives and subsequent coupling reaction with Boc-amino acid furnished the corresponding dipeptides, which were transformed to dipeptide containing α,β -didehydroamino acid with high *E* selectivity.

Much attention has been focused on naturally occurring peptides containing α,β -didehydroamino acids¹ and their derivatives from the view point of both synthetic interest and the relationship between their structure and bioactivities.²

Therefore, much work related to the preparation of α,β -didehydroamino acids has been reported in which the products bearing thermodynamically controlled alkene geometry, (*Z*)- α,β -didehydroamino acids were predominantly formed.³ In previous papers, we have reported that *N*-*t*-butoxycarbonyl (Boc)- or *N*-benzyloxycarbonyl (*Z*)- α -tosylglycine ester was reacted with either a variety of nitro alkanes in the presence of base or various aldehydes in the presence of base and tributylphosphine to afford the corresponding α,β -didehydroamino acid derivatives with high *Z* selectivity in good yields.⁴ The latter procedure was successfully applied to the synthesis of optically active 4-hydroxyprolines.⁵


On the contrary, there are few reports⁶ concerning stereoselective synthesis of (*E*)- α,β -didehydroamino acid since its stereochemistry is not always thermodynamically favored, for example, 1) stereoselective elimination of hydrogen chloride from *erythro*- β -chloro- α -amino acid derived from *threo*- β -hydroxy- α -amino acid derivative,^{6a} 2) stereospecific dehydration of *erythro*- β -hydroxy- α -amino acid derivative using DAST [(diethylamino)sulfur trifluoride],^{6b} 3) formation of cyclic *cis*-sulfamidite starting from *erythro*- β -hydroxy- α -amino acid derivative and thionyl chloride, and subsequent elimination of sulfur dioxide,^{6c} 4) Suzuki coupling of β -bromo- α,β -didehydroamino acid derivative with monosubstituted boronic acid,^{6d} 5) stereospecific dehydration of *erythro*- β -hydroxy- α -amino acid derivative using Martin's sulfurane [diphenylbis(1,1,1,3,3,3-hexafluoro-2-phenyl-2-propyl)sulfurane],^{6e} 6) stereospecific dehydration of *threo*- β -hydroxy- α -amino acid derivative with EDC [1-ethyl-3-(3-dimethylaminopropyl)carbodiimide],^{6f} 7) oxidation of 3-*S*-benzylthioamino acid derivative to the sulfoxide, followed by thermolysis to form α,β -didehydroamino acid.^{3b}

Although enantiomerically pure β -hydroxy- α -amino acid derivative or β -bromo- α,β -didehydroamino acid derivative is

required for preparation of the starting material as mentioned above,^{3b,6} we now wish to report a new and effective stereoselective synthesis of (*E*)- α,β -didehydroamino acid derivative **1** via *cis*-4,5-oxazolidinone derivative **2** starting from methyl *N*-Boc-*N*-phenoxy-carbonyl-glycinate **3f** and a variety of aldehydes **4** according to retrosynthetic analysis as shown in Scheme 1. The present method is characterized by stereospecific formation of *erythro*- β -hydroxy- α -amino acid derivative in situ through aldol reaction of **3f** with a variety of aldehydes **4**, simultaneous conversion to *cis*-4,5-oxazolidinone derivative **2**, which is stereoselectively transformed into (*E*)- α,β -didehydroamino acid derivative **1**, and the simplicity of experimental procedure for the preparation.

First, we prepared methyl *N,N*-diprotected glycines **3a–3f** by the reaction of methyl *N*-monoprotected glycinate **5a–5f** with di-*t*-butyl dicarbonate (Boc₂O). Methyl Boc-glycinate (**5a**) was treated with 2 molar equivalents of Boc₂O in the presence of 0.3 molar equivalents of 4-(dimethylamino)pyridine (DMAP) in dry acetonitrile to afford the desired methyl *N,N*-bis(*t*-butoxycarbonyl)glycinate (**3a**)⁷ in quantitative yield (Entry 1 in Table 1). Similarly, methyl *N,N*-diprotected glycines **3b–3f** were also prepared in good yields as shown in Table 1 (Entries 2–6).


Next, formation of *cis*-4,5-oxazolidinone derivatives through the reaction of ester enolates of **3a–3f** with benzaldehyde (**4i**) was examined as a preliminary experiment. The results are



Scheme 1. Retrosynthetic analysis of (*E*)-didehydroamino acid derivative.

Table 1. Preparation of Various *N,N*-Diprotected Glycine Methyl Esters

		$\text{P}_G\text{-NHCH}_2\text{CO}_2\text{CH}_3 \xrightarrow[\text{CH}_3\text{CN, Temp, Time}]{\text{Boc}_2\text{O, DMAP}} \text{P}_G(\text{Boc})\text{NCH}_2\text{CO}_2\text{CH}_3$					
		5a-f				3a-f	
Entry	Substrate	P _G	Boc ₂ O /mol equiv	DMAP /mol equiv	Reaction conditions		Product/%
					Temp/°C	Time/h	
1	5a	Boc	2.0	0.3	55	22	3a quant
2	5b	Z	1.5	0.2	rt	2	3b 77
3	5c	Cl ₃ CH ₂ CO ₂ C	1.1	0.1	rt	0.3	3c 98
4	5d	H ₃ CO ₂ C	1.5	0.2	rt	2	3d 90
5	5e	H ₃ CH ₂ CO ₂ C	1.2	0.1	rt	0.3	3e quant
6	5f	PhO ₂ C	1.1	0.1	−5	3	3f quant


Table 2. Preparation of *cis*-4,5-Oxazolidinone Derivatives

Entry	Substrate	P _G	Temp/°C	Time/h	Yield of 2i /%
1	3a	Boc	−78	0.5	— ^{a)}
2	3a	Boc	−78	2	— ^{b)}
3	3a	Boc	−78–rt	4.5	— ^{c)}
4	3b	Z	−78	6	trace ^{d)}
5	3c	Cl ₃ CH ₂ CO ₂ C	rt	1	trace ^{e)}
6	3d	H ₃ CO ₂ C	−78	3	32 ^{f)}
7	3e	H ₃ CH ₂ CO ₂ C	−78–rt	1.5	40
8	3f	PhO ₂ C	−78	1	63

a) Methyl 2-(*t*-butoxycarbonylamino)-3-(*t*-butoxycarbonyloxy)-3-phenylpropanoate (**6**) was obtained in 85% yield. b) 56% of compound **6** and 11% of methyl (*Z*)-*N*-Boc- α,β -didehydrophenylalaninate (**1i'**) were obtained. c) A mixture of **1i'** and methyl (*E*)-*N*-Boc- α,β -didehydrophenylalaninate (**1i**) was obtained in 36% and 25% yields, respectively. d) Recovery of **3b** in 38% yield. e) Recovery of **3c** in 45% yield along with 37% of **5c**. f) Recovery of **3d** in 16% yield.

summarized in Table 2. Lithiation of **3a** with 1.1 molar equivalents of lithium diisopropylamide (LDA) in tetrahydrofuran (THF) at −78 °C for 1 h followed by the reaction of the lithium ester enolate thus prepared with 1.1 molar equivalents of benzaldehyde (**4i**) at −78 °C for 30 min did not afford the desired product **2i**, but methyl 2-(*t*-butoxycarbonylamino)-3-(*t*-butoxycarbonyloxy)-3-phenylpropanoate (**6**) in 85% yield (Entry 1 in Table 2). Although the substrates **3b** and **3c** were treated with benzaldehyde (**4i**) under similar reaction conditions, no product **2i** was obtained (Entries 4 and 5 in Table 2). A plausible reaction mechanism for formation of **6** and methyl (*Z*)- or (*E*)-*N*-Boc- α,β -didehydrophenylalaninate (**1i'**^{3b,3h,8} and **1i**) may be explained as follows: the lithium ester enolate derived from **3a** was reacted with benzaldehyde (**4i**) to afford the lithium alkoxide of methyl *N,N*-diBoc- β -phenylserinate. Subsequently, the lithium alkoxide anion attacked the carbonyl carbon atom of the *N*-Boc group resulting in

formation of **6** through a five-membered cyclic intermediate. Namely, it reveals that N, O migration of the Boc group took place during the reaction as shown in Scheme 2. Accordingly, in Entry 1, quenching the reaction mixture afforded only **6** in 85% yield, while a mixture of **6** and **1i'** due to elimination of carbon dioxide and lithium *tert*-butoxide for longer reaction time as shown in Entry 2, and a mixture of **1i** and **1i'** at elevated temperature in Entry 3 (in Table 2) were furnished, respectively. Reversibly, in the cases of the substrates **3d–3f**, the desired product **2i** as a single isomer was obtained in 32%, 40%, and 63% yields, respectively (Entries 6–8 in Table 2). Although the difference between the results using **3a–3f** is now not clear, the result in Entry 8 may be attributed to stabilities of **3f** under these reaction conditions and of the leaving phenoxide anion. The structure of product **2i** was confirmed by comparison of its ¹H NMR data with those of the known compound reported by Naito et al.^{9a} and NOE measurement. The chemical shifts and coupling constant (*J* = 8.90 Hz) between the hydrogens at the C4–C5 position of **2i** are fully in agreement with those of the reported values (*J* = 9.0 Hz).^{9a,9b} Eventually, it was found that the stereochemical relationship between the hydrogens at the C4–C5 position is a *cis* configuration. As compound **3f** among **3a–3f** examined was found to be a useful starting material for construction of the *cis*-4,5-oxazolidinone system, the reaction of compound **3f** with a variety of aldehydes **4a–4h** and **4j–4l** was examined. The results are listed in Table 3. When the lithium ester enolate derived from **3f** at −40 °C for 1 h in THF was reacted with 1.1 molar equivalents of acetaldehyde (**4a**) at −40 °C for 4 h, no product was obtained at all (Entry 1 in Table 3). After formation of the lithium ester enolate of **3f** at −78 °C **4a** was reacted at −40 or −78 °C for 4 h to furnish the desired product **2a** in moderate yields (Entries 2 and 3 in Table 3). In a similar manner, the products **2b** and **2c** were obtained in moderate yields by treating the reaction mixture at −78 to −40 °C for 4 h (Entries 4 and 5 in Table 3). In the absence of additive, **2e**, **2g**, and **2h** were produced only in 43%, 42%, and 31% yields, respectively (Entries 7, 9, and 10). In order to improve the yields by activation of the aldehydes **4e**, **4g**, and **4h** Lewis acids such as Ti(O^{*i*}Pr)₄ and Cl₂Ti(O^{*i*}Pr)₂ were used as an additive to produce the corresponding **2e**, **2g**, and **2h** in 66%, 51%, and 45% yields, respectively (Entries 7, 9, and 10 in Table 3). In the cases of aromatic aldehydes **4j–4l** the desired products **2j–2l** were also obtained in moderate yields (Entries 11–13 in Table 3).



Scheme 2.

Table 3. Preparation of Various Oxazolidinone Derivatives


$\text{PhO}_2\text{CNCH}_2\text{CO}_2\text{CH}_3 \xrightarrow[\text{N}_2, \text{THF}, -78^\circ\text{C}, 1\text{ h}]{\text{LDA (1.1 mol equiv)}} \xrightarrow[\text{Temp, Time}]{\text{RCHO (1.1 mol equiv), Additive (1.1 mol equiv)}} \text{Oxazolidinone derivative}$							
Entry	Aldehyde	R	Additive	Temp/ $^\circ\text{C}$	Time/h	Product	Yield/%
1 ^{a)}	4a	CH ₃ –	—	–40	4	2a	0
2	4a	CH ₃ –	—	–40	4	2a	51
3	4a	CH ₃ –	—	–78	4	2a	61
4	4b	CH ₃ CH ₂ –	—	–78––40	4	2b	52
5	4c	(CH ₃) ₂ CH–	—	–78––40	4	2c	46
6	4d	PhCH ₂ CH ₂ –	—	–78	4	2d	72
7	4e		Ti(O ^{<i>i</i>} Pr) ₄	–78	4	2e	66
8 ^{b)}	4f		—	–78	3	2f	41
9	4g		Cl ₂ Ti(O ^{<i>i</i>} Pr) ₂	–78	3	2g	51
10	4h	Boc(Z)NCH ₂ CH ₂ CH ₂ –	Cl ₂ Ti(O ^{<i>i</i>} Pr) ₂	–78	3	2h	45
11	4j	<i>p</i> -BrC ₆ H ₄ –	—	–78	48	2j	51
12	4k	<i>p</i> -CH ₃ C ₆ H ₄ –	—	–30	48	2k	55
13	4l	<i>p</i> -CH ₃ OC ₆ H ₄ –	—	–30	48	2l	60

a) The lithium ester enolate was prepared at -40°C . b) LiHMDS was used as base.

Stereoselective formation of 4,5-*cis*-oxazolidinone derivative **2** might be explained as follows. The silyl enol ester and the O-alkylated enol ester were first isolated to determine configuration of the lithium ester enolate formed in the solution. Namely, the lithium ester enolate derived from **3a** or **3f** with LDA at -78°C in THF was treated with excess of chlorotrimethylsilane, *t*-butyldimethylsilyl trifluoromethanesulfonate, *t*-butyldiphenylsilyl chloride (TBDPS-Cl), or benzyl bromide.¹⁰ Unfortunately all attempts failed. The reaction might proceed via TS 1 with the least steric hindrance among

TS 1 to TS 4 to afford the lithium alkoxide of the corresponding *erythro*- β -hydroxy- α -amino acid ester.¹¹ Subsequently, nucleophilic attack of the alkoxide anion thus formed onto the carbonyl carbon atom of the *N*-phenoxycarbonyl group might proceed and the subsequent elimination of the lithium phenoxide gives the desired *cis*-4,5-oxazolidinone derivative **2** as shown in Scheme 3.

As synthetic route to *cis*-4,5-oxazolidinone derivatives **2a–2l** starting from **3f** and aldehydes **4** was achieved, conversion of diastereomerically pure compounds **2a–2l** into (*E*)- α,β -dide-



Scheme 3. A plausible reaction mechanism.


Table 4. Conversion of Oxazolidinone Derivatives to (*E*)-Dehydroamino Acid Derivatives

Entry	Substrate ^{a)}	R	Temp/°C	Yield/%			
				E form		Z form	
1	2a	CH ₃ –	–40	1a	57	1a'	41
2 ^{b)}	2a	CH ₃ –	–78	1a	68	1a'	27
3 ^{c)}	2a	CH ₃ –	–100	1a	76	1a'	<24
4	2a	CH ₃ –	–78	1a	85	1a'	<13
5	2b	CH ₃ CH ₂ –	–78	1b	91	1b'	<9
6	2c	(CH ₃) ₂ CH–	–78	1c	96	1c'	<4
7	2d	PhCH ₂ CH ₂ –	–78	1d	96	1d'	<4
8 ^{d)}	2e	R'=Z	–10	1e	93	1e'	<7
9	2f	R'=Boc	–78	1f	82	1f'	<8
10	2g	R'=Z	–10	1g	48	1g'	25
11	2g	R'=Boc	–78	1g	83	1g'	<4
12	2h	Boc(Z)NCH ₂ CH ₂ CH ₂ –	–10	1h	62	1h'	25
13	2i	Ph–	–20	1i	92	1i'	6
14	2j	<i>p</i> -BrC ₆ H ₄ –	–20	1j	89	1j'	9
15	2k	<i>p</i> -CH ₃ C ₆ H ₄ –	–20	1k	92	1k'	6
16	2l	<i>p</i> -CH ₃ OC ₆ H ₄ –	–20	1l	91	1l'	7

a) Diastereomerically pure substrates **2a–2l** were used. b) HMPA (3.0 mol equiv) was added. c) Reacted for 30 min. d) Reacted for 10 min.

hydroamino acid derivatives **1a–1l** was examined under basic conditions. The results are listed in Table 4. Various bases such as 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), KO^tBu, KOH, and lithium hexamethyldisilazide (LiHMDS) in THF were used. Eventually, LiHMDS was base of choice among bases tested in THF to

afford α,β -didehydroamino acid derivatives **1a–1l** predominantly accompanied by α,β -didehydroamino acid derivatives **1a'–1l'**. Compound **2a** was treated with 3.0 molar equivalents of LiHMDS at –40 °C for 5 min to afford methyl 2-(*t*-butoxycarbonylamino)-2-butenate as a separable mixture of **1a** and **1a'** in 57% and 41% yields, respectively (Entry 1 in Table 4).

Scheme 4. Synthesis of (3*S*,5*S*)-3-(*Z*-amino)-5-(TBDPS-oxymethyl)- γ -lactone **7**.

Major product **1a** was assigned to be (*E*)-2-(*t*-butoxycarbonylamino)-2-butenate by comparison with the reported ^1H NMR data^{3b} and by NOE measurement. Minor product **1a'** proved to be methyl (*Z*)-2-(*t*-butoxycarbonylamino)-2-butenate by comparison with the reported ^1H NMR data.^{3b,3c,3i,8a} On treatment of **2a** with 3.0 molar equivalents of LiHMDS at -100°C for 30 min, stereoselectivity of *E* and *Z* isomers (**1a/1a'**) was improved considerably (Entry 3 in Table 4). Moreover, **2a** was reacted at -78°C for 5 min to afford compound **1a** in 85% yield (Entry 4). Predominant formation of **1a** from **2a** might be due to trans elimination by deprotonation with base at the α -position of the ester group.^{3h} In a similar manner, compounds (*E*)-**1b–1l** were stereoselectively prepared in moderate to high yields (Entries 5–16). Stereochemistry of **1b**, **1d–1g**, and **1i–1l** were assigned by NOE measurement without **1c** and **1h**, whose stereochemistry were determined by isomerization to the corresponding **1c'** and **1h'** using a catalytic amount of I_2 (Entries 6 and 12 in Table 4).¹² The ^1H NMR spectra of **1a'**,^{3b,3c,3i,8a} **1b'**,^{8a} **1c'**,^{8a} **1d'**,¹³ **1i'**,^{3b,8a–8c} **1k'**,¹⁴ and **1l'**¹⁵ were satisfactorily in accordance with the reported data of *Z* isomer.

Because it was found that compounds **2** could be stereoselectively converted into (*E*)- α,β -didehydroamino acid derivatives **1** the present method was employed for synthesis of (3*S*,5*S*)-3-(benzyloxycarbonylamino)-5-(*t*-butyldiphenylsiloxy)- γ -lactone (**7**),¹⁶ known as a key synthetic intermediate of the antibiotic clavalanine¹⁷ isolated from *streptomyces clavuligerus* according to Scheme 4. First, compound **8** was prepared as the starting material as shown in Table 5. After **3f** was treated with 1.1 molar equivalents of LDA at -78°C for 30 min, the resulting lithium ester enolate was reacted with 1.5 molar equivalents of (*R*)-*O*-2,3-isopropylidene-glyceraldehyde at -78°C for 4 h to afford a separable mixture of two diastereomers, of which **8a** was produced as an oil and **8a'** in crystalline form in 22% and 30% yields, respectively (Entry 1 in Table 5). As 15.2% and 11.4% NOE between the hydrogens at C4–C5 in irradiation of the proton at C4 in products **8a** and **8a'** were observed, the stereochemistry between the hydrogens at C4–C5 of the oxazolidinone ring is assigned to be *cis* configuration. To improve the total yield various reaction

Table 5. Preparation of Oxazolidinone **8**

Entry	Additive	X /mol equiv	Temp / $^\circ\text{C}$	Time /h	Yield/%	
					8a	8a'
1	—	—	-78	4	22	30
2	—	—	-78 – -10	3	10	24
3	—	—	-78 – -20	24	<22	<28
4	$\text{TiCl}_4 \cdot 2\text{THF}$	1.5	-78	2	26	—
5	$\text{Ti}(\text{O}^i\text{Pr})_4$	0.5	-78	2	24	20
6	$\text{Ti}(\text{O}^i\text{Pr})_4$	0.5	-78	4	<28	13
7	$\text{Ti}(\text{O}^i\text{Pr})_4$	1.1	-78	4	32	16
8	$\text{Ti}(\text{O}^i\text{Pr})_4$	1.1	-78	6	30	21
9	$\text{Ti}(\text{O}^i\text{Pr})_4$	1.5	-78	2	40	<25
10	$\text{Ti}(\text{O}^i\text{Pr})_4$	2.0	-78	4	38	19


conditions were examined. Accordingly, the ratio of two diastereomers was found to be dependent on reaction conditions (Entries 2–10 in Table 5).

Each of diastereomerically pure compounds **8a** and **8a'** thus obtained was individually exposed to the conditions for preparation of α,β -didehydroamino acid via elimination of carbon dioxide as described for preparation of compound **1**. The results are summarized in Table 6. Thus, treatment of **8a** (oily form) with 3.0 molar equivalents of LiHMDS at -10°C for 5 min furnished compound **9** in a ratio of 78:22 as a mixture of *E* and *Z* isomers¹⁸ in 70% yield (Entry 2 in Table 6). Similarly, **8a'** (crystalline form) was reacted with 3.0 molar equivalents of LiHMDS at -30°C for 90 min in THF to afford

the desired product **9** in a ratio of 85:15 as a mixture of E and Z isomers in 87% yield (Entry 5 in Table 6). Formation of a mixture of (*E*)- and (*Z*)-**9** might be explained as follows: the carbanion generated by deprotonation with LiHMDS undergoes trans elimination of carbon dioxide with retention of stereochemistry to afford (*E*)-**9**, however, (*Z*)-**9** is produced due to formation of the ester enolate.

Next, conversion of the mixture of diastereomers **9** into compound **7** was performed according to Scheme 4. Treatment of the mixture of diastereomers **9** (E/Z = 78:22) with 1 M HCl in MeOH at room temperature for 1 day gave the desired γ -butenolide derivative **10**¹⁹ and methyl (4*S*)-(Z)-2-(*N*-Boc-amino)-4,5-dihydroxy-2-pentenoate in 61% and 19% yields, respectively. Formation of the latter product was probably attributed to deacetalization of the starting Z isomer **9** since the authentic Z isomer **9** prepared by an alternative way⁵ afforded only the deacetalization product in 90% yield under the same reaction conditions. Therefore, E isomer **9** was cyclized to the oxazolidinone derivative **10**, whereas Z isomer **9** underwent deacetalization. Next, compound **10** was reacted with 1.2 molar equivalents of TBDPS-Cl in the presence of 3 molar equivalents of imidazole at room temperature for 4 h in dimethylformamide (DMF) to afford O-protected product **11** in 80% yield. Hydrogenation of the resulting compound **11**

Table 6. Conversion of Oxazolidinone **8** to Dehydroamino Acid Derivative **9**




Entry	Substrate ^{a)}	Temp/°C	Time/min	Yield/%	E/Z
1	8a	−10	3	50	76/24
2	8a	−10	5	70	78/22
3	8a	−30	60	61	77/23
4	8a'	−10	5	73	89/11
5	8a'	−30	90	87	85/15

a) Stereoisomerically pure substrates **8a** and **8a'** were used.

over 20% Pd(OH)₂-carbon in EtOH under hydrogen atmosphere at room temperature for 10 h took place stereospecifically from the less hindered side due to the bulky TBDPS-oxymethyl substituent at position 5 to afford exclusively cis 3,5-disubstituted γ -lactone derivative **12** as a single isomer in 89% yield,⁵ whereas in the case of longer (overnight) reaction time, a mixture of cis and trans isomers was obtained in 62% and 13% yields, respectively. N-Deprotection of the resulting compound **12** by trifluoroacetic acid (TFA) at 0 °C to room temperature for 1 h in dichloromethane and subsequent coupling reaction with 1.1 molar equivalents of *N*-(benzyloxycarbonyloxy)succinimide (Z-ONSu) in the presence of 3 molar equivalents of triethylamine (TEA) at 0 °C to room temperature for 2 h in THF afforded the desired compound **7** in 80% yield.


In a previous paper,¹² we reported that isomerization of dipeptide containing (*E*)-*N*-Boc- α,β -didehydroamino acid residue to the corresponding *Z* isomer could be readily performed by means of a catalytic amount of iodine. Indeed, stereochemically pure methyl (*E*)-2(*N*-*t*-butoxycarbonylamino)-2-butenate (**1a**) was treated with a catalytic amount of iodine at room temperature for 19 h in THF to furnish the corresponding *Z* isomer **1a'** in 90% yield (Entry 1 in Table 7). In a similar way, pure *E* isomers **1b–1h** were smoothly isomerized to the corresponding *Z* isomers **1b'–1h'** in high yields. The ¹H NMR data of the products **1a'–1h'** produced by isomerization were satisfactorily identical with those of the minor products obtained in Entries 4–12 in Table 4. The results are summarized in Table 7.

We next tried to prepare the amide compounds **13a**–**13k'** by the reaction of diastereomerically pure *cis*-4,5-oxazolidinones **2a**, **2d**, and **2i** with *N*-Boc amino acid derivatives as shown in Table 8. Thus, after N-deprotection of **2i** with 99% formic acid at room temperature for 40 min, the resulting oxazolidinone derivative was treated with 1.1 molar equivalents of LDA at -78°C for 5 min in dry THF followed by reaction with 1.1 molar equivalents of the *N*-hydroxysuccinimide (HONSu) ester of Boc-alanine at -78 to -10°C for 3 h to afford the corresponding amide product **13i** as a major product and **13i'** as a minor one in 96% total yields as a separable mixture of

Table 7. Isomerization of E to Z Isomer by Iodine

Entry	Substrate ^{a)}	R	Time/h	Yield/%	E/Z	
1	1a	CH ₃ –	19	1a'	90	4/96
2	1b	CH ₃ CH ₂ –	17	1b'	91	3/97
3	1c	(CH ₃) ₂ CH–	21	1c'	96	5/95
4	1d	PhCH ₂ CH ₂ –	12	1d'	98	3/97
5	1e	 R' = Z	24	1e'	97	4/96
6	1f	 R' = Boc	43	1f'	93	9/91
7	1g		16	1g'	quant	0/100
8	1h	Boc(Z)NCH ₂ CH ₂ CH ₂ –	9	1h'	96	0/100

a) A stereochemically pure E isomer of **1a–1h** was used.

Table 8. Coupling of Boc-Amino Acid with *cis*-4,5-Oxazolidinone Derivative

Entry	Substrate ^{a)}	R	AA ^{b)}	Product	Total yield/%	dr ^{c)}
1	2a	CH ₃	Gly	13a	82	—
2			Ala	13b/13b'	68	53/47
3			Val	13c/13c'	60	52/48
4			Leu	13d/13d'	78	51/49
5	2d	PhCH ₂ CH ₂	Gly	13e	94	—
6			Ala	13f/13f'	60	52/48
7			Val	13g/13g'	62	52/48
8	2i	Ph	Gly	13h	92	—
9			Ala	13i/13i'	96	53/47
10			Val	13j/13j'	92	51/49
11			Leu	13k/13k'	98	55/45

a) A diastereomerically pure isomer of **2a**, **2d**, and **2i** was used.

b) Means amino acid abbreviated by three letters. c) Means the ratio of the two diastereomers.

two diastereomers with a ratio of 53:47 as shown in Table 8 (Entry 9). Similarly, compounds **13a–13h** (Entries 1–8) and **13j–13k'** (Entries 10 and 11) were prepared in satisfactory yields as a separable mixture of two diastereomers without Entries 1, 5, and 8.

We next tried to prepare the dipeptide containing (*E*)- α,β -didehydroamino acid residue as shown in Table 9. Compound **13b**, the major product, thus obtained was treated with 4.0 molar equivalents of LiHMDS at $-45\text{ }^\circ\text{C}$ for 50 min in THF to afford the corresponding dipeptide **14b** and **14b'** in a ratio of 84:16 in 88% yield (Entry 2 in Table 9). Treatment of **13b'**, the minor product, with LiHMDS under the same reaction conditions also resulted in the formation of **14b** and **14b'** in a ratio of 81:19 in 92% yield (Entry 3 in Table 9). The major product **14b** was found to be methyl (*E*)-2-(Boc-alanyl-amino)-2-butenate, and **14b'** to be (*Z*)-2-(Boc-alanyl-amino)-2-butenate compared with the reported data^{3i,6f,20} and NOE measurement of **14b**. From these results, it was found that treatment of both **13b** and **13b'** bearing *cis*-4,5-oxazolidinone moiety with base afforded the dipeptide **14b** bearing (*E*)- α,β -didehydroamino acid residue predominantly with high stereoselectivity accompanied by *Z* isomer **14b'** as in the case described for conversion of **2** to **1**. In the same way, compounds **14a** and **14c–14k** containing α,β -didehydroamino acid with high *E* selectivity were prepared in good yields. The results are listed in Table 9. Stereochemistry of the major products, **14a**, **14c**, **14d**, and **14f–14k** was assigned to be *E* configuration by NOE measurement. Stereochemistry of the major product **14e** was determined by

Table 9. Conversion of Compounds **13a–13k'** to the Corresponding Dipeptides **14a–14k'**

13a-k'

LiHMDS (4.0 mol equiv)
 THF, $-45\text{ }^\circ\text{C}$, 50 min

14a-k'

Entry	Substrate	R	AA	Product	Yield/%	E/Z
1	13a	CH ₃	Gly	14a/14a'	56	81/19
2	13b		Ala	14b/14b'	88	84/16
3	13b'		Ala	14b/14b'	92	81/19
4	13c		Val	14c/14c'	95	85/15
5	13c'		Val	14c/14c'	85	85/15
6	13d		Leu	14d/14d'	61	88/12
7	13d'		Leu	14d/14d'	52	75/25
8	13e	PhCH ₂ CH ₂	Gly	14e/14e'	52	88/12
9	13f		Ala	14f/14f'	80	85/15
10	13f'		Ala	14f/14f'	75	84/16
11	13g		Val	14g/14g'	72	89/11
12	13g'		Val	14g/14g'	80	87/13
13	13h	Ph	Gly	14h/14h'	53	85/15
14	13i		Ala	14i/14i'	78	87/13
15	13i'		Ala	14i/14i'	82	87/13
16	13j		Val	14j/14j'	70	89/19
17	13j'		Val	14j/14j'	74	91/9
18	13k		Leu	14k/14k'	59	89/11
19	13k'		Leu	14k/14k'	60	88/12

isomerization to the minor product **14e'** by means of I_2 .¹² The minor products, **14a'**,^{3h,3i,20} **14h'**,^{3h} and **14i'**,^{3b,3c} were found to be the dipeptide containing (*Z*)- α,β -didehydroamino acid residue according to the reported ¹H NMR data.

As mentioned above, the reaction of compound **3f** derived from glycine with a variety of aldehydes **4** afforded various kinds of *cis*-4,5-oxazolidinone derivatives **2**, which were readily transformed to the corresponding α,β -didehydroamino acid derivatives with high *E* selectivity in good yields under basic conditions. Thus, **3f** was found to be a very useful building block for the preparation of (*E*)- α,β -didehydroamino acid. Moreover, (*E*)- α,β -didehydroamino acid derivatives thus prepared were satisfactorily isomerized to the corresponding (*Z*)- α,β -didehydroamino acid derivatives by using iodine. Eventually, the present method will supply a convenient preparation method for both (*E*)- and (*Z*)- α,β -didehydroamino acid derivatives. In addition, the amide compounds **13** were easily transformed to the corresponding dipeptides **14** containing (*E*)- α,β -didehydroamino acid residue under basic conditions.

Experimental

All of the melting points were determined with a micro melting apparatus (Yanagimoto Seisakusho) and are uncorrected. The ¹H NMR, IR, and MS spectra were recorded on JEOL JNM-LA 400FT (400 MHz) and LA 300FT (300 MHz) NMR spectrometers, a JASCO FT/IR-230 infrared spectrometer, and a JEOL SX-102A mass spectrometer, respectively. The chemical shifts of the NMR spectra are reported in δ -relative to TMS as an internal standard. All solvents were distilled and stored over a drying agent. Thin-layer chromatography (TLC) and flash-column chromatography

were performed using Merck's silica gel 60PF₂₅₄ (Art. 7749) and Cica-Merck's silica gel 60 (No. 9385-5B), respectively. All crystalline products prepared in the present work were colorless.

A General Procedure for Conversion of Oxazolidinones 2a–2l to (E)- α,β -Didehydroamino Acid Derivatives 1a–1l. To a solution of **2a** (81 mg, 0.31 mmol) in dry THF (5 mL) was added LiHMDS (1.55 mmol) in THF at -78°C under N_2 . The solution was stirred for 5 min at that temperature and quenched with 1 M AcOH in THF. The solvent was removed in vacuo to give a residue, which was partitioned between ethyl acetate (EtOAc) and water. The EtOAc solution was washed with brine, dried over MgSO_4 , and concentrated under reduced pressure. The residue was subjected to preparative TLC (SiO_2 , hexane/EtOAc = 4/1, v/v) to afford methyl (E)-2-(Boc-amino)-2-butenolate (**1a**) in 85% (57 mg) and Z isomer, **1a'** in <13% yields, respectively. (E)-**1a**: oil; IR (neat): 3457, 3420, 3358, 2979, 2954, 2932, 2394, 2287, 1728, 1651, 1511, 1439, 1365, 1254, 1200, 1163, 1116, 1051, 1013, 937, 888, 850, 829, 800, 771, 703 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.47 (s, 9H), 2.03 (d, $J = 11.71$ Hz, 3H), 3.86 (s, 3H), 6.57 (br, 1H), 6.78 (br, 1H). HRMS (FAB^+) ($M^+ + 1$): Found: m/z 216.1241. Calcd for $\text{C}_{10}\text{H}_{18}\text{NO}_4$: 216.1236. When the β -methyl protons were irradiated, 9.0% and 1.9% NOE were observed for the olefinic proton and the protons of the methyl ester, respectively. (Z)-**1a'**: mp 72.5–73.5 $^\circ\text{C}$ (EtOAc–hexane) (Lit. mp 69–71 $^\circ\text{C}$).^{8a} IR (KBr): 3330, 3168, 3007, 2978, 2952, 1722, 1642, 1608, 1586, 1545, 1468, 1455, 1436, 1366, 1329, 1307, 1246, 1220, 1161, 1085, 1048, 1026, 985, 937, 910, 850, 793, 756, 698 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.47 (s, 9H), 1.81 (d, $J = 7.32$ Hz, 3H), 3.77 (s, 3H), 5.86–6.10 (br, 1H), 6.68 (q, $J = 7.32$ Hz, 1H). Found: C, 55.60; H, 8.02; N, 6.51%. Calcd for $\text{C}_{10}\text{H}_{17}\text{NO}_4$: C, 55.80; H, 7.96; N, 6.51%.

The physical and spectral data of compounds **1b–1l** and **1b'–1l'** are shown in the following.

Methyl 2-(N-Boc-amino)-2-pentenoate (1b and 1b'): (E)-**1b**: oil; IR (neat): 3457, 3419, 3360, 2977, 2935, 2876, 2287, 1707, 1645, 1512, 1457, 1438, 1391, 1366, 1248, 1163, 1050, 1020, 978, 934, 876, 832, 816, 772, 702 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.09 (t, $J = 7.55$ Hz, 3H), 1.47 (s, 9H), 2.54 (quintet, $J = 7.55$ Hz, 2H), 3.82 (s, 3H), 6.55 (br, 1H), 6.88 (br, 1H). HRMS (FAB^+) ($M^+ + 1$): Found: m/z 230.1390. Calcd for $\text{C}_{11}\text{H}_{20}\text{NO}_4$: 230.1392. When the methyl ester protons were irradiated, 4.0% and 2.6% NOE were observed for the methylene and the methyl protons of the ethyl group. (Z)-**1b'**: oil (Lit. oil);^{8a} IR (neat): 3340, 3120, 2976, 2936, 2877, 1709, 1657, 1496, 1457, 1438, 1391, 1366, 1310, 1247, 1160, 1110, 1049, 1020, 988, 917, 884, 848, 799, 776, 734, 692 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.06 (t, $J = 7.56$ Hz, 3H), 1.46 (s, 9H), 2.24 (quintet, $J = 7.56$ Hz, 2H), 3.77 (s, 3H), 6.02 (br, 1H), 6.53 (t, $J = 7.56$ Hz, 1H). HRMS (FAB^+) ($M^+ + 1$): Found: m/z 230.1386. Calcd for $\text{C}_{11}\text{H}_{20}\text{NO}_4$: 230.1392.

Methyl (N-Boc)- α,β -didehydroleucinate (1c and 1c'): (E)-**1c**: oil IR (neat): 3419, 3357, 2969, 2934, 2870, 1729, 1708, 1644, 1513, 1466, 1438, 1366, 1334, 1249, 1161, 1046, 1024, 855, 772 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.05 (d, $J = 6.59$ Hz, 6H), 1.47 (s, 9H), 3.22–3.31 (m, 1H), 3.82 (s, 3H), 6.37–6.50 (br, 2H). HRMS (FAB^+) ($M^+ + 1$): Found: m/z 244.1555. Calcd for $\text{C}_{12}\text{H}_{22}\text{NO}_4$: 244.1549. (Z)-**1c'**: oil (Lit. mp 74–75 $^\circ\text{C}$).^{8a} IR (neat): 3340, 3119, 2964, 2933, 2871, 1710, 1657, 1495, 1438, 1366, 1315, 1258, 1161, 1119, 1049, 1028, 998, 958, 942, 915, 890, 843, 796, 778, 765, 742 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.05 (d, $J = 7.87$ Hz, 6H), 1.46 (s, 9H), 2.63–2.79 (m, 1H), 3.77 (s, 3H), 5.92 (br, 1H), 6.38 (d, $J = 10.09$ Hz, 1H). HRMS (FAB^+) ($M^+ + 1$): Found: m/z 244.1559. Calcd for $\text{C}_{12}\text{H}_{22}\text{NO}_4$: 244.1549.

Methyl 2-(N-Boc-amino)-5-phenyl-2-pentenoate (1d and 1d'): (E)-**1d**: oil; IR (neat): 3417, 3358, 3086, 3061, 3027, 2979, 2952, 2931, 2860, 2287, 1947, 1727, 1707, 1646, 1604, 1510, 1454, 1438, 1391, 1367, 1243, 1200, 1162, 1094, 1048, 1026, 897, 868, 836, 770, 750, 700 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.47 (s, 9H), 2.76–2.81 (m, 2H), 2.81–2.88 (m, 2H), 3.79 (s, 3H), 6.58 (br, 1H), 6.76 (br, 1H), 7.19–7.28 (m, 5H). HRMS (FAB^+) ($M^+ + 1$): Found: m/z 306.1709. Calcd for $\text{C}_{17}\text{H}_{24}\text{NO}_4$: 306.1705. When the methyl protons of the ester group were irradiated, 1.3% and 1.8% NOE were observed for the γ,δ -methylene protons and the phenyl protons, respectively. (Z)-**1d'**: oil (Lit. mp 48 $^\circ\text{C}$).¹⁴ IR (neat): 3339, 3086, 3062, 3027, 2978, 2952, 2931, 1725, 1657, 1604, 1496, 1454, 1437, 1391, 1367, 1269, 1246, 1165, 1085, 1049, 1031, 1003, 912, 882, 845, 798, 775, 749, 700 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.46 (s, 9H), 2.47 (q, $J = 7.80$ Hz, 2H), 2.77 (t, $J = 7.80$ Hz, 2H), 3.76 (s, 3H), 5.86 (br s, 1H), 6.58 (t, $J = 7.80$ Hz, 1H), 7.20–7.34 (m, 5H). HRMS (FAB^+) ($M^+ + 1$): Found: m/z 306.1702. Calcd for $\text{C}_{17}\text{H}_{24}\text{NO}_4$: 306.1705.

Methyl α -(N-Boc)- β -(N'-Z)- α,β -didehydrotryptophanate (1e and 1e'): (E)-**1e**: mp 113.0–113.5 $^\circ\text{C}$ (EtOAc–hexane). IR (KBr): 3898, 3851, 3733, 3708, 3687, 3674, 3647, 3627, 3415, 2954, 2357, 1745, 1695, 1507, 1457, 1441, 1405, 1360, 1322, 1280, 1238, 1161, 1088, 1043, 910, 756, 704 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.52 (s, 9H), 3.70 (s, 3H), 5.47 (s, 2H), 7.25–7.41 (m, 6H), 7.48 (d, $J = 7.81$ Hz, 2H), 7.59 (d, $J = 8.05$ Hz, 1H), 7.74 (s, 1H), 8.07 (s, 1H), 8.17 (d, $J = 8.07$ Hz, 1H). HRMS (FAB^+) ($M^+ + 1$): Found: m/z 451.1875. Calcd for $\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_6$: 451.1869. When the N–H proton of the carbamate was irradiated, 2.8% NOE was observed for the olefinic proton. (Z)-**1e'**: mp 107.5–108.5 $^\circ\text{C}$ (EtOAc–hexane). IR (KBr): 3340, 2978, 2953, 2934, 1714, 1660, 1495, 1455, 1437, 1391, 1382, 1367, 1350, 1275, 1244, 1165, 1097, 1047, 1008, 949, 899, 835, 797, 774, 764, 728, 695 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.56 (s, 9H), 3.87 (s, 3H), 5.46 (s, 2H), 6.22 (br, 1H), 7.31–7.49 (m, 7H), 7.59 (s, 1H), 7.72 (d, $J = 7.07$ Hz, 1H), 7.92 (s, 1H), 8.20 (d, $J = 7.79$ Hz, 1H). Found: C, 66.60; H, 5.82; N, 6.26%. Calcd for $\text{C}_{25}\text{H}_{26}\text{N}_2\text{O}_6$: C, 66.65; H, 5.82; N, 6.22%.

Methyl α -(N-Boc)- β -(N'-Boc)- α,β -didehydrotryptophanate (1f and 1f'): (E)-**1f**: mp 130.5–131.0 $^\circ\text{C}$ (EtOAc–hexane). IR (KBr): 3854, 3735, 3650, 3452, 3188, 2980, 2359, 1727, 1712, 1629, 1519, 1455, 1435, 1398, 1339, 1309, 1257, 1237, 1212, 1148, 1093, 1045, 1028, 986, 922, 849, 765, 741, 725 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.52 (s, 9H), 1.68 (s, 9H), 3.75 (s, 3H), 6.85 (s, 1H), 7.25–7.32 (m, 2H), 7.57 (d, $J = 7.56$ Hz, 1H), 7.76 (s, 1H), 8.05 (s, 1H), 8.13 (d, $J = 8.05$ Hz, 1H). Found: C, 63.09; H, 6.85; N, 6.67%. Calcd for $\text{C}_{22}\text{H}_{28}\text{N}_2\text{O}_6$: C, 63.44; H, 6.78; N, 6.73%. When the olefinic proton was irradiated, 1.3% and 1.0% NOE were observed for the *t*-butyl protons of the Boc group and the N–H proton of the carbamate, respectively. (Z)-**1f'**: mp 145.0–146.0 $^\circ\text{C}$ (EtOAc–hexane). IR (KBr): 3324, 2978, 1734, 1641, 1584, 1545, 1482, 1454, 1435, 1370, 1330, 1308, 1250, 1153, 1086, 1049, 1019, 987, 935, 858, 839, 794, 741 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.45 (s, 9H), 1.68 (s, 9H), 3.64 (s, 3H), 6.17 (s, 1H), 7.29–7.36 (m, 2H), 7.59 (s, 1H), 7.70 (d, $J = 7.83$ Hz, 1H), 7.94 (s, 1H), 8.15 (d, $J = 8.03$ Hz, 1H). Found: C, 63.40; H, 6.84; N, 6.75%. Calcd for $\text{C}_{22}\text{H}_{28}\text{N}_2\text{O}_6$: C, 63.44; H, 6.78; N, 6.73%.

Methyl α -(N-Boc)- β -(N'-Boc)- α,β -didehydrohistidinate (1g and 1g'): (E)-**1g**: mp 147.5–149.0 $^\circ\text{C}$ (EtOAc–hexane). IR (KBr): 3389, 3137, 3124, 2983, 2949, 2359, 1736, 1656, 1545, 1496, 1478, 1435, 1390, 1374, 1352, 1308, 1276, 1256, 1225, 1159,

1118, 1050, 1026, 1011, 986, 965, 895, 873, 837, 770 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.49 (s, 9H), 1.62 (s, 9H), 3.84 (s, 3H), 6.79 (s, 1H), 7.24 (s, 1H), 7.84 (s, 1H), 8.01 (s, 1H). Found: C, 55.48; H, 6.96; N, 11.31%. Calcd for $\text{C}_{17}\text{H}_{25}\text{N}_3\text{O}_6$: C, 55.57; H, 6.86; N, 11.44%. When the N–H proton of the carbamate was irradiated, 1.8% NOE was observed for the olefinic proton. (Z)-**1g'**: mp 120.5–121.5 $^\circ\text{C}$ (EtOAc–hexane). IR (KBr): 3300, 3134, 2981, 1755, 1738, 1718, 1649, 1550, 1466, 1393, 1368, 1331, 1257, 1234, 1214, 1156, 1063, 1013, 839, 805, 770 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.48 (s, 9H), 1.63 (s, 9H), 3.84 (s, 3H), 6.42 (s, 1H), 7.37 (s, 1H), 8.09 (s, 1H), 9.04 (s, 1H). Found: C, 55.59; H, 6.98; N, 11.27%. Calcd for $\text{C}_{17}\text{H}_{25}\text{N}_3\text{O}_6$: C, 55.57; H, 6.86; N, 11.44%.

Methyl α -(N-Boc)- ϵ -(N'-Boc-N'-Z)- α,β -didehydrolysinate (1h and 1h'): (E)-**1h**: oil; IR (neat): 3365, 3065, 3033, 2979, 2935, 2401, 2291, 1790, 1738, 1588, 1500, 1479, 1456, 1369, 1342, 1286, 1247, 1208, 1154, 1047, 973, 916, 854, 780, 753, 699 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.46 (s, 9H), 1.47 (s, 9H), 1.75 (tt, $J = 7.51, 7.69$ Hz, 2H), 2.52 (dt, $J = 7.70, 7.72$ Hz, 2H), 3.68 (t, $J = 7.70$ Hz, 2H), 3.78 (s, 3H), 5.22 (s, 2H), 6.55 (br, 1H), 6.66 (br, 1H), 7.29–7.40 (m, 5H). HRMS (FAB $^+$) ($M^+ + 1$): Found: m/z 493.2564. Calcd for $\text{C}_{25}\text{H}_{37}\text{N}_2\text{O}_8$: 493.2550. (Z)-**1h'**: oil; IR (neat): 3342, 2979, 1789, 1723, 1497, 1456, 1368, 1287, 1159, 1114, 1047, 915, 854, 778, 698 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.45 (s, 9H), 1.47 (s, 9H), 1.75 (quintet, $J = 7.52$ Hz, 2H), 2.22 (dt, $J = 7.15, 7.52$ Hz, 2H), 3.66 (t, $J = 7.52$ Hz, 2H), 3.75 (s, 3H), 5.22 (s, 2H), 6.12 (br, 1H), 6.49 (t, $J = 7.15$ Hz, 1H), 7.30–7.40 (m, 5H). HRMS (FAB $^+$) ($M^+ + 1$): Found: m/z 493.2545. Calcd for $\text{C}_{25}\text{H}_{37}\text{N}_2\text{O}_8$: 493.2550.

Methyl 2-(N-Boc-amino)-3-phenylpropenoate (1i and 1i'): (E)-**1i**: oil; IR (neat): 3333, 2979, 1715, 1636, 1514, 1490, 1437, 1368, 1244, 1157, 1057, 1026, 984, 919, 857, 833, 754, 698 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.50 (s, 9H), 3.63 (s, 3H), 6.68–6.74 (br, 1H), 7.21–7.32 (m, 5H), 7.40–7.60 (br, 1H). EI-MS m/z 277 (M^+ ; 6.12%). When the N–H proton was irradiated, 3.1% and 1.0% NOE were observed for the olefinic proton and the protons of the methyl ester. (Z)-**1i**: mp 76.0–77.0 $^\circ\text{C}$ (hexane) (Lit. mp 81–82 $^\circ\text{C}$,^{8a} 77–79 $^\circ\text{C}$,^{8b}); IR (KBr): 3327, 2990, 2946, 1721, 1700, 1644, 1488, 1445, 1369, 1287, 1242, 1206, 1163, 1143, 1079, 1063, 990, 841, 761, 690 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.40 (s, 9H), 3.86 (s, 3H), 6.06–6.24 (br, 1H), 7.25 (s, 1H), 7.31–7.40 (m, 3H), 7.52–7.55 (m, 2H). Found: C, 64.80; H, 6.97; N, 5.09%. Calcd for $\text{C}_{15}\text{H}_{19}\text{NO}_4$: C, 64.97; H, 6.91; N, 5.05%.

Methyl 3-(p-Bromophenyl)-2-(N-Boc-amino)propenoate (1j and 1j'): (E)-**1j**: oil; IR (neat): 3333, 2979, 1725, 1715, 1636, 1514, 1490, 1437, 1368, 1244, 1157, 1057, 1026, 984, 919, 857, 833, 754, 698 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.50 (s, 9H), 3.65 (s, 3H), 6.72–6.82 (br, 1H), 7.10 (d, $J = 8.44$ Hz, 2H), 7.41 (d, $J = 8.44$ Hz, 2H), 7.45–7.55 (br, 1H). EI-MS m/z 355 (M^+ ; 10.02%). When the N–H proton of the carbamate was irradiated, 3.5% and 1% NOE were observed for the olefinic proton and both ortho protons of the aromatic ring, respectively. (Z)-**1j'**: mp 121.0–122.0 $^\circ\text{C}$ (EtOAc–hexane). IR (KBr): 3327, 2990, 2946, 1721, 1700, 1644, 1488, 1445, 1369, 1287, 1242, 1206, 1163, 1143, 1063, 990, 841, 761, 690 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.40 (s, 9H), 3.86 (s, 3H), 6.20–6.30 (br, 1H), 7.19 (s, 1H), 7.39 (d, $J = 8.62$ Hz, 2H), 7.48 (d, $J = 8.62$ Hz, 2H). Found: C, 50.47; H, 5.17; N, 3.85%. Calcd for $\text{C}_{15}\text{H}_{18}\text{NO}_4\text{Br}$: C, 50.58; H, 5.09; N, 3.93%.

Methyl 2-(N-Boc-amino)-3-(p-tolyl)propenoate (1k and 1k'): (E)-**1k**: oil; IR (neat): 3355, 2979, 1725, 1708, 1637, 1607, 1507, 1485, 1438, 1368, 1248, 1159, 1050, 1023, 984, 845, 815,

775 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.49 (s, 9H), 2.33 (s, 3H), 3.66 (s, 3H), 6.62–6.70 (br, 1H), 7.09 (d, $J = 8.34$ Hz, 2H), 7.14 (d, $J = 8.34$ Hz, 2H), 7.38–7.48 (br, 1H). EI-MS m/z 291 (M^+ ; 15.51%). When the N–H proton of the carbamate was irradiated, 2.8% NOE was observed for the olefinic proton. (Z)-**1k'**: mp 88.0–89.0 $^\circ\text{C}$ (hexane) (Lit. 87–90 $^\circ\text{C}$).^{8c} IR (KBr): 3339, 2971, 1708, 1631, 1605, 1488, 1444, 1369, 1342, 1272, 1172, 1136, 1049, 1024, 987, 921, 820, 795, 775 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.41 (s, 9H), 2.36 (s, 3H), 3.85 (s, 3H), 6.07–6.17 (br, 1H), 7.17 (d, $J = 8.07$ Hz, 2H), 7.25–7.48 (br, 1H), 7.44 (d, $J = 8.07$ Hz, 2H). Found: C, 65.66; H, 7.48; N, 4.71%. Calcd for $\text{C}_{16}\text{H}_{21}\text{NO}_4$: C, 65.96; H, 7.27; N, 4.81%.

Methyl 2-(N-Boc-amino)-3-(p-methoxyphenyl)propenoate (1l and 1l'): (E)-**1l**: oil; IR (neat): 3338, 2979, 1723, 1637, 1607, 1512, 1438, 1368, 1302, 1248, 1161, 1030, 985, 919, 824 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.49 (s, 9H), 3.68 (s, 3H), 3.81 (s, 3H), 6.60–6.70 (br, 1H), 6.83 (d, $J = 8.90$ Hz, 2H), 7.21 (d, $J = 8.90$ Hz, 2H), 7.34–7.44 (br, 1H). EI-MS m/z 307 (M^+ ; 15.51%). When the N–H proton of the carbamate was irradiated, 4.1% NOE was observed for the olefinic proton. (Z)-**1l'**: mp 111.0–112.0 $^\circ\text{C}$ (EtOAc–hexane). IR (KBr): 3338, 2979, 1703, 1638, 1604, 1515, 1442, 1360, 1321, 1259, 1181, 1145, 1055, 1030, 992, 826, 779 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.49 (s, 9H), 3.79 (s, 3H), 3.80 (s, 3H), 6.69–6.77 (br, 1H), 6.82 (d, $J = 8.80$ Hz, 2H), 7.26–7.40 (br, 1H), 7.51 (d, $J = 8.80$ Hz, 2H). Found: C, 62.32; H, 7.03; N, 4.47%. Calcd for $\text{C}_{16}\text{H}_{21}\text{NO}_5$: C, 62.53; H, 6.89; N, 4.56%.

A General Procedure for the Preparation of cis-4,5-Oxazolidin-2-one Derivatives (2a–2l). To a solution of **3f** (93 mg, 0.30 mmol) in dry THF (1.5 mL) was added 1.1 molar equivalents of LDA at -78 $^\circ\text{C}$ under N_2 . After the solution was stirred at that temperature for 1 h, a solution of benzaldehyde (**4i**) (35 mg, 0.33 mmol) in THF (1.5 mL) was added dropwise and the solution was kept at -78 $^\circ\text{C}$ for 1 h. The reaction was then quenched with 1 M AcOH in MeOH and the solvent was concentrated under reduced pressure. The residue was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc and the combined extracts were washed with brine, dried over MgSO_4 , and evaporated in vacuo. The residual oil was subjected to preparative TLC (SiO_2 , hexane/EtOAc = 5/1, v/v) to give 3-Boc-4-(methoxycarbonyl)-5-phenyl-cis-4,5-oxazolidin-2-one (**2i**) in 63% yield (203 mg). Mp 129.0–130.0 $^\circ\text{C}$ (EtOAc–hexane) (Lit. mp 114–115 $^\circ\text{C}$).^{9a} IR (KBr): 2976, 1803, 1750, 1723, 1457, 1441, 1388, 1365, 1312, 1260, 1218, 1189, 1167, 1088, 1050, 1006, 927, 861, 837, 786, 766, 699 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.51 (s, 9H), 3.25 (s, 3H), 4.95 (d, $J = 8.90$ Hz, 1H), 5.71 (d, $J = 8.90$ Hz, 1H), 7.28–7.40 (m, 2H), 7.50–7.55 (m, 3H). Found: C, 59.59; H, 6.19; N, 4.31%. Calcd for $\text{C}_{16}\text{H}_{19}\text{NO}_6$: C, 59.81; H, 5.96; N, 4.36%. When the proton at C-4 was irradiated, 12.0% and 2.4% NOE were observed for the proton at C-5 and both ortho protons of the aromatic ring. When the proton at C-5 was irradiated, 15.1% and 11.0% NOE were observed for the proton at C-4 and both ortho protons of the aromatic ring.

The physical and spectral data of compounds **2a–2h** and **2j–2l** are shown in the following.

3-Boc-4-methoxycarbonyl-5-methyl-cis-4,5-oxazolidin-2-one (2a): Mp 78.5–79.5 $^\circ\text{C}$ (EtOAc–hexane); IR (KBr): 3007, 2977, 2954, 2939, 2884, 1826, 1759, 1724, 1701, 1587, 1463, 1442, 1396, 1371, 1327, 1299, 1281, 1260, 1220, 1185, 1160, 1120, 1074, 1025 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.38 (d, $J = 6.34$ Hz, 3H), 1.51 (s, 9H), 3.83 (s, 3H), 4.72 (d, $J = 8.78$ Hz, 1H), 4.78 (dq, $J = 6.34, 8.78$ Hz, 1H). Found: C, 50.88; H, 6.67; N, 5.46%.

Calcd for $C_{11}H_{17}NO_6$: C, 50.96; H, 6.61; 5.40%. When the protons of the methyl ester were irradiated, 1.0%, 1.82%, and 1.34% NOE were observed for the proton at C-4, both *t*-butyl protons of the Boc group and the methyl protons at C-5, respectively.

3-Boc-5-ethyl-4-methoxycarbonyl-*cis*-4,5-oxazolidin-2-one (2b): Mp 60.0–63.0 °C (EtOAc–hexane); IR (KBr): 3007, 2977, 2954, 2939, 2884, 1826, 1759, 1724, 1701, 1463, 1442, 1396, 1371, 1327, 1299, 1281, 1260, 1220, 1185, 1160, 1120, 1074, 925 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$): δ 1.08 (t, J = 7.34 Hz, 3H), 1.51 (s, 9H), 1.59–1.68 (m, 2H), 3.81 (s, 3H), 4.51 (dt, J = 4.56, 8.44 Hz, 1H), 4.72 (d, J = 8.44 Hz, 1H). Found: C, 52.62; H, 7.09; N, 5.07%. Calcd for $C_{12}H_{19}NO_6$: C, 52.74; H, 7.01; N, 5.13%.

3-Boc-4-methoxycarbonyl-5-isopropyl-*cis*-4,5-oxazolidin-2-one (2c): Mp 82.0–84.0 °C (EtOAc–hexane); IR (KBr): 2982, 1824, 1787, 1747, 1371, 1361, 1339, 1331, 1248, 1213, 1188, 1161, 1125, 1096, 1050, 1026, 988 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$): δ 1.02 (d, J = 6.40 Hz, 3H), 1.08 (d, J = 6.40 Hz, 3H), 1.51 (s, 9H), 1.72–1.79 (m, 2H), 3.81 (s, 3H), 4.15 (dd, J = 7.52, 10.09 Hz, 1H), 4.72 (d, J = 7.52 Hz, 1H). Found: C, 54.04; H, 7.35; N, 4.77%. Calcd for $C_{13}H_{21}NO_6$: C, 54.35; H, 7.37; N, 4.88%.

3-Boc-4-methoxycarbonyl-5-(2-phenylethyl)-*cis*-4,5-oxazolidin-2-one (2d): Mp 123.0–125.0 °C (EtOAc–hexane); IR (KBr): 2979, 1810, 1746, 1702, 1383, 1371, 1352, 1207, 1166, 1060, 1017, 977, 785, 775, 770 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$): δ 1.50 (s, 9H), 1.84–1.90 (m, 2H), 2.72–2.91 (m, 2H), 3.80 (s, 3H), 4.53 (dt, J = 4.95, 8.44 Hz, 1H), 4.68 (d, J = 8.44 Hz, 1H), 7.17–7.31 (m, 1H). Found: C, 61.82; H, 6.77; N, 4.01%. Calcd for $C_{18}H_{23}NO_6$: C, 61.88; H, 6.64; N, 4.01%.

3-Boc-4-methoxycarbonyl-5-[(*N'*-Z)-3'-indolyl]-*cis*-4,5-oxazolidin-2-one (2e): To a solution of **3f** (93 mg, 0.30 mmol) in dry THF (5 mL) was added 1.1 molar equivalents of LDA (0.33 mmol) at –78 °C under N_2 . After keeping at –78 °C for 1 h, a solution of **4e** (84 mg, 0.30 mmol) in dry THF (2 mL) was added followed by the addition of $Ti(O^iPr)_4$ (94 mg, 0.33 mmol). The solution was stirred at –78 °C for 4 h and quenched with 1 M AcOH in THF. After addition of a small amount of water, the mixture was passed through celite. The THF was removed under reduced pressure to give a residue, which was partitioned between EtOAc and water. The EtOAc solution was washed with brine, dried, and evaporated in vacuo to afford a residue, which was subjected to preparative TLC (SiO_2 , hexane/EtOAc = 3/1, v/v). 98 mg of **2e** was obtained. Mp 173.0–173.5 °C (EtOAc–hexane); IR (KBr): 2979, 1804, 1742, 1609, 1573, 1457, 1407, 1370, 1357, 1315, 1258, 1243, 1220, 1172, 1131, 1102, 1055, 996, 756 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 1.52 (s, 9H), 3.16 (s, 3H), 5.05 (d, J = 8.78 Hz, 1H), 5.43 (d, J = 12.20 Hz, 1H), 5.47 (d, J = 12.20 Hz, 1H), 5.95 (dd, J = 0.98, 8.78 Hz, 1H), 7.29–7.50 (m, 8H), 7.70 (s, 1H), 8.19 (d, J = 8.29 Hz, 1H). Found: C, 63.08; H, 5.33; N, 5.67%. Calcd for $C_{26}H_{26}N_2O_8$: C, 63.15; H, 5.30; N, 5.66%. When the proton at C-4 was irradiated, 17.5%, 4.3%, and 3.3% NOE were observed for the proton at C-5, 2-position of the indole ring and both the *t*-butyl protons of the Boc group.

3-Boc-4-methoxycarbonyl-5-[(*N'*-Boc)-3'-indolyl]-*cis*-4,5-oxazolidin-2-one (2f): Mp 152.0–153.0 °C (EtOAc); IR (KBr): 2981, 2367, 1800, 1742, 1655, 1596, 1559, 1542, 1508, 1458, 1356, 1318, 1258, 1224, 1154, 1131, 1101, 1051, 992, 844, 788, 770, 744 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 1.52 (s, 9H), 1.56 (s, 9H), 3.19 (s, 3H), 5.06 (d, J = 8.78 Hz, 1H), 5.98 (dd, J = 0.98, 8.78 Hz, 1H), 7.24–7.27 (m, 1H), 7.33–7.37 (m, 1H), 7.49 (d, J = 7.81 Hz, 1H), 7.65 (s, 1H), 8.17 (d, J = 8.29 Hz, 1H). Found:

C, 59.91; H, 6.25; N, 6.04%. Calcd for $C_{23}H_{28}N_2O_8$: C, 59.99; H, 6.13; N, 6.08%. When the proton at C-5 was irradiated, 15.9% NOE was observed for the proton at C-4.

3-Boc-4-methoxycarbonyl-5-[(*N'*-Boc)-4'-imidazolyl]-*cis*-4,5-oxazolidin-2-one (2g): Mp 138.0–139.0 °C (EtOAc); IR (KBr): 3003, 2979, 2935, 1819, 1802, 1750, 1725, 1399, 1368, 1328, 1312, 1276, 1248, 1219, 1190, 1156, 1091, 1069, 1020, 1006, 848, 776 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 1.51 (s, 9H), 1.61 (s, 9H), 3.60 (s, 3H), 5.01 (d, J = 8.78 Hz, 1H), 5.70 (d, J = 8.78 Hz, 1H), 7.44 (s, 1H), 8.04 (s, 1H). Found: C, 52.61; H, 6.21; N, 10.04%. Calcd for $C_{18}H_{25}N_3O_8$: C, 52.55; H, 6.13; N, 10.21%.

3-Boc-4-methoxycarbonyl-5-{3-[(*N'*-Boc)-*N'*-Z]aminopropyl]-*cis*-4,5-oxazolidin-2-one (2h): Mp 83.5–84.5 °C (EtOAc–hexane); IR (KBr): 2979, 1810, 1740, 1654, 1559, 1542, 1508, 1458, 1363, 1339, 1279, 1251, 1164, 1129, 1088, 984, 846, 773, 743, 696 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 1.47 (s, 9H), 1.50 (s, 9H), 1.50–1.90 (m, 4H), 3.64–3.74 (m, 2H), 3.77 (s, 3H), 4.56 (dt, J = 3.84, 8.61 Hz, 1H), 4.66 (d, J = 8.61 Hz, 1H), 5.21 (s, 2H), 7.29–7.39 (m, 5H). Found: C, 58.09; H, 6.79; N, 5.33%. Calcd for $C_{26}H_{36}N_2O_{10}$: C, 58.20; H, 6.76; N, 5.22%.

3-Boc-5-(*p*-bromophenyl)-4-methoxycarbonyl-*cis*-4,5-oxazolidin-2-one (2j): Mp 154.0–155.0 °C (EtOAc–hexane); IR (KBr): 2980, 1810, 1752, 1721, 1361, 1314, 1222, 1160, 1082, 1061, 1006, 846, 787, 774, 766, 694 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 1.51 (s, 9H), 3.32 (s, 3H), 4.96 (d, J = 8.90 Hz, 1H), 5.67 (d, J = 8.90 Hz, 1H), 7.20 (d, J = 8.35 Hz, 2H), 7.53 (d, J = 8.35 Hz, 2H). Found: C, 48.03; H, 4.59; N, 3.42%. Calcd for $C_{16}H_{18}NO_6Br$: C, 48.02; H, 4.53; N, 3.50%. When the α -proton of the ester group was irradiated, 13.8% NOE was observed for the β -proton.

3-Boc-4-methoxycarbonyl-5-(*p*-tolyl)-*cis*-4,5-oxazolidin-2-one (2k): Mp 128.0–129.0 °C (EtOAc–hexane); IR (KBr): 2979, 1801, 1749, 1721, 1365, 1318, 1216, 1186, 1171, 1091, 1048, 1007, 843, 810, 784, 767 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$): δ 1.51 (s, 9H), 2.35 (s, 3H), 3.29 (s, 3H), 4.94 (d, J = 8.99 Hz, 1H), 5.67 (d, J = 8.99 Hz, 1H), 7.18 (br s, 4H). Found: C, 60.71; H, 6.41; N, 4.16%. Calcd for $C_{17}H_{21}NO_6$: C, 60.89; H, 6.31; N, 4.18%. When the α -proton was irradiated, 13.3% NOE was observed for the β -proton.

3-Boc-4-methoxycarbonyl-5-(*p*-methoxyphenyl)-*cis*-4,5-oxazolidin-2-one (2l): Mp 140.0–141.00 °C (EtOAc–hexane); IR (KBr): 2979, 1802, 1747, 1721, 1614, 1518, 1447, 1367, 1314, 1251, 1225, 1177, 1161, 1090, 1052, 1034, 1002, 846, 776 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$): δ 1.50 (s, 9H), 3.32 (s, 3H), 3.81 (s, 3H), 4.92 (d, J = 8.99 Hz, 1H), 5.76 (d, J = 8.99 Hz, 1H), 6.89 (d, J = 8.80 Hz, 2H), 7.23 (d, J = 8.80 Hz, 2H). Found: C, 57.88; H, 6.04; N, 3.86%. Calcd for $C_{17}H_{21}NO_7$: C, 58.11; H, 6.02; N, 3.99%. When the α -proton of the ester group was irradiated, 12.4% NOE was observed for the β -proton.

A General Procedure for the Preparation of *N,N*-Diprotected Glycine Methyl Esters (3a–3f). A solution of methyl Boc-glycinate (482 mg, 2.55 mmol), Boc₂O (1.113 g, 5.10 mmol), and DMAP (93 mg, 0.761 mmol) in dry acetonitrile (CH_3CN) (5 mL) was stirred at 55 °C for 22 h. The solvent was then removed in vacuo to give a residue, which was partitioned between EtOAc and a saturated solution of NH_4Cl . The aqueous solution was extracted with EtOAc. The combined extracts were washed with brine and dried over $MgSO_4$, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (eluent; hexane/EtOAc = 10/1, v/v) to afford methyl *N,N*-diBoc-glycinate (**3a**) in quantitative yield (734 mg). Mp 59.0–59.5 °C (hexane); IR (KBr): 3001, 2978, 1756, 1731, 1694, 1435, 1412, 1383, 1368, 1335, 1231, 1146, 1127, 991, 962, 897, 862, 848, 788, 768 cm^{-1} ;

^1H NMR (400 MHz, CDCl_3): δ 1.50 (s, 18H), 3.75 (s, 3H), 4.34 (s, 2H). Found: C, 53.70; H, 7.95; N, 4.74%. Calcd for $\text{C}_{13}\text{H}_{23}\text{NO}_6$: C, 53.97; H, 8.01; N, 4.84%.

The physical and spectral data of compounds **3b–3f** are shown in the following.

Methyl N-Boc-N-Z-glycinate (3b): Oil; IR (neat): 2979, 1801, 1761, 1699, 1456, 1439, 1415, 1370, 1343, 1258, 1217, 1182, 1153, 1107, 1004, 951, 916, 855, 780, 752, 698 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.46 (s, 9H), 3.71 (s, 3H), 4.41 (s, 2H), 5.24 (s, 2H), 7.30–7.40 (m, 5H). HRMS (FAB $^+$) ($M^+ + 1$): Found: m/z 324.1451. Calcd for $\text{C}_{16}\text{H}_{22}\text{NO}_6$: 324.1447.

Methyl N-Boc-N-2,2,2-trichloroethoxycarbonylglycinate (3c): Mp 51.0–51.5 $^{\circ}\text{C}$ (heptane); IR (KBr): 2982, 2957, 1812, 1756, 1708, 1439, 1416, 1371, 1346, 1255, 1221, 1156, 1062, 1019, 956, 855, 816, 778, 720 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.54 (s, 9H), 3.76 (s, 3H), 4.47 (s, 2H), 4.82 (s, 2H). Found: C, 35.99; H, 4.44; N, 3.82%. Calcd for $\text{C}_{11}\text{H}_{16}\text{NO}_6\text{Cl}_3$: C, 36.24; H, 4.42; N, 3.84%.

Methyl N-Boc-N-methoxycarbonylglycinate (3d): Oil; IR (neat): 2980, 2958, 1804, 1764, 1703, 1444, 1410, 1369, 1347, 1224, 1155, 1112, 1010, 948, 855, 783 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.50 (s, 9H), 3.76 (s, 3H), 3.84 (s, 3H), 4.40 (s, 2H). HRMS (FAB $^+$) ($M^+ + 1$): Found: m/z 248.1134. Calcd for $\text{C}_{10}\text{H}_{18}\text{NO}_6$: 248.1134.

Methyl N-Boc-N-ethoxycarbonylglycinate (3e): Oil; IR (neat): 2981, 1803, 1736, 1724, 1700, 1478, 1439, 1418, 1371, 1344, 1223, 1156, 1108, 1025, 959, 926, 893, 856, 782 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.32 (t, $J = 7.15$ Hz, 3H), 1.50 (s, 9H), 3.76 (s, 3H), 4.28 (q, $J = 7.15$ Hz, 2H), 4.40 (s, 2H). HRMS (FAB $^+$) ($M^+ + 1$): Found: m/z 262.1296. Calcd for $\text{C}_{11}\text{H}_{20}\text{NO}_6$: 262.1291.

Methyl N-Boc-N-phenoxy carbonylglycinate (3f): Mp 56.5–57.5 $^{\circ}\text{C}$ (hexane); IR (KBr): 2980, 1810, 1753, 1712, 1594, 1494, 1413, 1369, 1347, 1201, 1148, 1099, 1075, 1001, 959, 855, 777, 754 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.54 (s, 9H), 3.79 (s, 3H), 4.52 (s, 2H), 7.14–7.40 (m, 5H). Found: C, 57.94; H, 6.19; N, 4.54%. Calcd for $\text{C}_{15}\text{H}_{19}\text{NO}_6$: C, 58.24; H, 6.19; N, 4.53%.

4-(N-Boc-N-Z-amino)butanal (4h). 4-(N-Boc-N-Z-amino)-butanal (**4h**) in Table 3 was prepared starting from 4-amino-1-butanol.

To a solution of oxalyl chloride (0.96 mL, 11 mmol) in dry CH_2Cl_2 (25 mL) added DMSO (2.13 mL, 30 mmol)²¹ at -78°C under N_2 . After 15 min, a solution of **17** (3.24 g, 10 mmol) in CH_2Cl_2 (10 mL) was added and the solution was stirred for 15 min at that temperature. After addition of TEA (10.5 mL, 75 mmol) the mixture was gradually warmed to room temperature and then stirred for 1 h. The solvent was removed in vacuo to give a residue, which was partitioned between EtOAc, Et_2O , and water. The organic layer was dried over MgSO_4 and evaporated in vacuo to afford a residual oil which was subjected to silica gel column chromatography (eluent, hexane/EtOAc = 2/1, v/v). Compound **4h** was obtained in 90% yield (2.90 g). Oil; IR (neat): 2979, 2936, 2823, 2723, 1790, 1724, 1498, 1455, 1369, 1342, 1294, 1264, 1202, 1154, 1119, 1065, 1031, 1003, 854, 779, 752, 669 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.47 (s, 9H), 1.86–1.95 (m, 2H), 2.43 (t, $J = 7.33$ Hz, 2H), 3.69 (t, $J = 7.15$ Hz, 2H), 5.22 (s, 2H), 7.33–7.38 (m, 5H), 9.71 (s, 1H). HRMS (FAB $^+$) ($M^+ + 1$): Found: m/z 322.1656. Calcd for $\text{C}_{17}\text{H}_{24}\text{NO}_5$: 322.1654.

Methyl 2-(Boc-amino)-3-(*t*-butoxycarbonyloxy)-3-phenylpropanoate (6). To a solution of **3a** (277 mg, 0.79 mmol) in dry THF (4 mL) was added 1.1 molar equivalents of LDA at -78°C under N_2 . After the solution was stirred at that temperature

for 1 h, a solution of benzaldehyde (**4i**) (92 mg, 0.87 mmol) in THF (4 mL) was added dropwise at -78°C and the solution was kept at -78°C for 1 h. After quenching the reaction at that temperature with 0.5 M HCl in MeOH, the solvent was removed in vacuo to give a residue, which was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc. The combined extracts were washed with brine dried over MgSO_4 , and evaporated in vacuo. The residue was subjected to preparative TLC (SiO_2 , hexane/EtOAc = 7/1, v/v) to afford methyl 2-(Boc-amino)-3-(*t*-butoxycarbonyloxy)-3-phenylpropanoate (**6**) in 85% yield (265 mg). Mp 84.0–85.0 $^{\circ}\text{C}$ (EtOAc–hexane); IR (KBr): 3404, 2979, 1750, 1702, 1519, 1369, 1287, 1252, 1160, 1090, 1029, 968, 872, 760, 709 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.41 (s, 9H), 1.47 (s, 9H), 3.70 (s, 3H), 4.95–5.05 (m, 2H), 5.93 (d, $J = 4.03$ Hz, 1H), 7.29–7.39 (m, 5H). Found: C, 60.58; H, 7.51; N, 3.45%. Calcd for $\text{C}_{20}\text{H}_{29}\text{NO}_7$: C, 60.75; H, 7.39; N, 3.54%.

(3S,5S)-3-(N-Z-amino)-5-(*t*-butyldiphenylsiloxy)methyl- γ -lactone (7). To compound **12** (180 mg, 0.38 mmol) in CH_2Cl_2 (0.5 mL) was added TFA (0.5 mL) at 0°C under N_2 . The solution was stirred for 1 h at room temperature, and the solvent was removed in vacuo to afford a residue, which was dissolved in THF (3 mL). To the solution was added a solution of TEA (116 mg, 1.15 mmol) in THF (0.5 mL) followed by the addition of *N*-benzyloxycarbonyloxysuccinimide (Z-ONSu) (144 mg, 0.58 mmol). The solution was allowed to stir for 2 h at room temperature. After evaporation of the solvent the residue was partitioned between EtOAc and water. The EtOAc was washed with brine, dried over MgSO_4 , and evaporated in vacuo to give a residue, which was subjected to preparative TLC (SiO_2 , hexane/EtOAc = 3/1, v/v). The desired product **7** was obtained in 80% yield (155 mg). Oil; $[\alpha]_D^{25} + 3.96^{\circ}$ (c 0.88, EtOH) [Lit, $[\alpha]_D^{25} + 3.9^{\circ}$ (c 2.1, EtOH)];¹⁶ IR (neat): 3331, 3070, 2931, 2858, 1786, 1713, 1588, 1525, 1471, 1455, 1428, 1362, 1328, 1259, 1198, 1113, 1058, 1027, 997, 935, 907, 823, 777, 742, 703 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.05 (s, 9H), 2.06–2.18 (m, 1H), 2.66–2.74 (m, 1H), 3.74 (dd, $J = 4.04$, 11.55 Hz, 1H), 3.90 (dd, $J = 2.38$, 11.55 Hz, 1H), 4.53–4.59 (br, 2H), 5.13 (s, 2H), 5.30 (br, 1H), 7.30–7.46 (m, 11H), 7.63–7.67 (m, 4H). HRMS (FAB $^+$) ($M^+ + 1$): Found: m/z 504.2197. Calcd for $\text{C}_{29}\text{H}_{34}\text{NO}_5\text{Si}$: 504.2206.

3-Boc-4-methoxycarbonyl-5-(2,2-dimethyl-[1,3]dioxolane-4-yl)-*cis*-4,5-oxazolidin-2-one (8a and 8a'). To a solution of **3f** (309 mg, 1.0 mmol) in dry THF (6 mL) was added 1.1 molar equivalents of LDA (1.1 mmol) at -78°C and the solution was stirred for 30 min at that temperature. A solution of (*R*)-*O*-2,3-isopropylideneglyceraldehyde (195 mg, 1.5 mmol) in dry THF (5 mL) was added dropwise at -78°C followed by the addition of $\text{Ti}(\text{O}^i\text{Pr})_4$ (427 mg, 1.5 mmol). The resulting solution was allowed to stir for 2 h at -78°C and quenched with 1 M AcOH in THF at that temperature. After evaporation of the solvent, the residue was partitioned between EtOAc and water. The EtOAc solution was washed with brine, dried over MgSO_4 , and concentrated under reduced pressure to afford a residue. The crude product was separated by preparative TLC (SiO_2 , hexane/EtOAc = 3/1, v/v) to afford the oxazolidinone derivatives **8a** (oily form, 138 mg) in 40% and **8a'** (crystalline form, <86 mg) in <25% yields, respectively. **8a**: oil; IR (neat): 2985, 2937, 1828, 1758, 1730, 1479, 1457, 1438, 1372, 1333, 1255, 1215, 1157, 1068, 846, 771 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 1.31 (s, 3H), 1.42 (s, 3H), 1.50 (s, 9H), 3.81 (s, 3H), 3.99 (dd, $J = 3.67$, 8.62 Hz, 1H), 4.08–4.16 (m, 2H), 4.50 (m, 1H), 4.84 (d, $J = 8.62$ Hz, 1H). HRMS (FAB $^+$) ($M^+ + 1$): Found: m/z 346.1505. Calcd for $\text{C}_{15}\text{H}_{24}\text{NO}_8$: 346.1502. When the proton at C-4 position was irradiated, 15.2% and 1.3%

NOE were observed for the proton at C-5 and the methyl protons of the ester group, respectively. **8a'**: mp 189.0–191.0 °C (EtOAc–hexane). IR (KBr): 2992, 2939, 2899, 1807, 1759, 1723, 1458, 1369, 1337, 1218, 1158, 1103, 1070, 1033, 992, 973, 916, 862, 839, 785, 766 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.34 (s, 3H), 1.41 (s, 3H), 1.51 (s, 9H), 3.79 (s, 3H), 3.96 (dd, *J* = 6.24, 8.62 Hz, 1H), 4.12 (dd, *J* = 6.79, 8.62 Hz, 1H), 4.29 (ddd, *J* = 3.85, 6.24, 6.79 Hz, 1H), 4.58 (dd, *J* = 3.85, 8.80 Hz, 1H), 4.74 (d, *J* = 8.80 Hz, 1H). Found: C, 51.89; H, 6.77; N, 4.09%. Calcd for C₁₅H₂₃NO₈: C, 52.17; H, 6.71; N, 4.06%. When the proton at C-4 was irradiated, 11.4% and 1.0% NOE were observed for the proton at C-5 and methyl protons of the ester group, respectively.

Methyl (4S)-2-(N-Boc-amino)-4,5-isopropylidenedioxy-2-pentenoate (Mixture of E- and Z-9). To a solution of **8a** (65 mg, 0.188 mmol) in dry THF was added 3.0 molar equivalents of LiHMDS (0.564 mmol) at –10 °C under N₂ and the solution was stirred for 5 min at that temperature. The reaction was quenched with 1 M AcOH in THF and the solvent was removed in vacuo to give a residue, which was partitioned between EtOAc and water. The EtOAc solution was washed with brine, dried over MgSO₄, and evaporated in vacuo to afford a residue, which was subjected to preparative TLC (SiO₂, hexane/EtOAc = 3/1, v/v). The desired product **9** was obtained as a mixture of E and Z isomers in a ratio of 78:22 in 70% yield (40 mg). IR (neat): 3417, 3340, 2983, 2935, 2875, 1725, 1653, 1512, 1456, 1439, 1369, 1345, 1246, 1158, 1058, 1021, 845, 761 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): E isomer: δ 1.39 (s, 3H), 1.45 (s, 3H), 1.47 (s, 9H), 3.65 (dd, *J* = 7.52, 7.89 Hz, 1H), 3.85 (s, 3H), 4.25 (dd, *J* = 6.60, 8.05 Hz, 1H), 5.34 (dd, *J* = 6.60, 13.94 Hz, 1H), 6.70 (br s, 1H), 6.88 (d, *J* = 7.34 Hz, 1H). Z isomer: δ 1.39 (s, 3H), 1.45 (s, 3H), 1.46 (s, 9H), 3.80 (s, 3H), 3.81–3.86 (m, 1H), 4.34 (dd, *J* = 6.60, 8.62 Hz, 1H), 4.85 (dd, *J* = 6.60, 14.67 Hz, 1H), 6.40 (d, *J* = 8.25 Hz, 1H), 6.44 (br s, 1H). HRMS (FAB⁺) (*M*⁺ + 1) Found: 302.1599. Calcd for C₁₄H₂₄NO₆: 302.1604.

(4S)-2-(N-Boc-amino)-5-hydroxymethylbutenolide (10). A solution of compound **9** (E/Z = 78/22, 160 mg, 0.53 mmol) and 1 M HCl in MeOH (2.0 mL) was stirred for 1 d under air. After neutralization with NaHCO₃ solution at 0 °C, the solvent was removed in vacuo to give a residue, which was partitioned between EtOAc and water. The organic solution was washed with brine, dried over MgSO₄, and concentrated under reduced pressure. The residue was purified with preparative TLC (SiO₂, hexane/EtOAc = 1/1, v/v) to afford the product **10** in 61% yield (74 mg). Mp 123.0–124.0 °C (EtOAc–hexane); [α]_D²⁵ +18.14° (*c* 0.19, CHCl₃); IR (KBr): 3425, 2979, 1767, 1662, 1538, 1456, 1370, 1344, 1315, 1241, 1160, 1075, 1045, 1016, 934, 888, 849, 770 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.50 (s, 9H), 2.30–2.44 (br, 1H), 3.71 (dd, *J* = 5.69, 12.29 Hz, 1H), 3.97 (dd, *J* = 3.30, 12.29 Hz, 1H), 5.14 (m, 1H), 6.82–6.98 (br, 1H), 7.04–7.08 (br, 1H). Found: C, 52.12; H, 6.63; N, 6.05%. Calcd for C₁₀H₁₅NO₅: C, 52.40; H, 6.60; N, 6.11%.

(4S)-2-(N-Boc-amino)-5-(*t*-butyldiphenylsiloxy)methylbutenolide (11). A solution of **10** (85 mg, 0.37 mmol), TBDPS-Cl (123 mg, 0.45 mmol), and imidazole (76 mg, 1.12 mmol) in DMF (3 mL) was allowed to stir for 4 h at room temperature. The reaction solution was diluted with water and extracted with ether. The ethereal solution was washed with brine, dried over MgSO₄, and evaporated in vacuo to give a residue which was subjected to preparative TLC (SiO₂, hexane/EtOAc = 3/1, v/v). The desired product **11** was obtained as oil in 80% yield (132 mg). [α]_D²⁵ +25.84° (*c* 1.18, EtOH); IR (neat): 3421, 3317, 3134, 3071, 3049, 2959, 2931, 2893, 2858, 2741, 2344, 1961, 1768, 1734, 1667,

1589, 1519, 1472, 1428, 1392, 1369, 1344, 1316, 1237, 1158, 1115, 1085, 1045, 1010, 937, 904, 857, 823, 772, 742, 703 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.03 (s, 9H), 1.50 (s, 9H), 3.76 (dd, *J* = 4.95, 11.00 Hz, 1H), 3.89 (dd, *J* = 4.22, 11.00 Hz, 1H), 5.05–5.09 (m, 1H), 6.77 (br, 1H), 6.97 (br, 1H), 7.36–7.42 (m, 5H), 7.62–7.66 (m, 5H). HRMS (FAB⁺) (*M*⁺ + 1): Found: *m/z* 468.2208. Calcd for C₂₆H₃₄NO₅Si: 468.2206.

(3S,5S)-3-(N-Boc-amino)-5-(*t*-butyldiphenylsiloxy)methyl-γ-lactone (12). Compound **11** (94 mg, 0.21 mmol) was hydrogenated over 20% palladium hydroxide on carbon (12 mg) in EtOH (3 mL) at room temperature under hydrogen atmosphere for 10 h. Then, the catalyst was filtered through a pad of celite, and the filtrate was removed in vacuo. The residual oil was subjected to preparative TLC (SiO₂, hexane/EtOAc = 3/1, v/v) to afford compound **12** in 89% yield (88 mg). Oil; [α]_D²⁵ +3.56° (*c* 1.25, EtOH); IR (neat): 3351, 3071, 3050, 2964, 2931, 2894, 2859, 1962, 1894, 1784, 1713, 1589, 1510, 1473, 1456, 1428, 1391, 1367, 1328, 1291, 1254, 1164, 1114, 1051, 1030, 978, 936, 911, 871, 823, 742, 704 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.06 (s, 9H), 1.46 (s, 9H), 2.03–2.11 (m, 1H), 2.66–2.81 (br, 1H), 3.74 (dd, *J* = 3.90, 11.50 Hz, 1H), 3.89 (dd, *J* = 2.93, 11.50 Hz, 1H), 4.44–5.16 (br, 1H), 4.48–4.55 (m, 2H), 7.36–7.47 (m, 6H), 7.64–7.68 (m, 4H). HRMS (FAB⁺) (*M*⁺ + 1): Found: *m/z* 470.2360. Calcd for C₂₆H₃₆NO₅Si: 470.2363.

A General Procedure for Coupling Reaction of Boc-Amino Acid with *cis*-4,5-Oxazolidinone Derivatives (13a–13k'). A solution of 3-Boc-4-(methoxycarbonyl)-5-phenyl-*cis*-4,5-oxazolidin-2-one (**2i**) (321 mg, 1.0 mmol) in 99% formic acid (20 mL) was allowed to stand for 40 min. Evaporation of the solvent afforded the N-deprotected oxazolidinone derivative in quantitative yield (mp 147–148 °C from EtOAc–hexane). To the resulting oxazolidinone (221 mg, 1.0 mmol) in dry THF (5 mL) was added dropwise 1.1 molar equivalents of LDA at –78 °C under N₂. After 5 min a solution of Boc-Ala-ONSu (429 mg, 1.1 mmol) in THF (5 mL) was added at –78 °C followed by the addition of a solution of DMAP (12 mg, 0.1 mmol) in dry THF (2 mL). The solution was then warmed to –10 °C and kept at that temperature for 3 h. After quenching the reaction with 1 M AcOH in THF at –78 °C, the solvent was removed in vacuo to give a residue, which was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc. The combined EtOAc extracts were washed with a solution of 10% NaHCO₃ and brine, dried over MgSO₄, and concentrated under reduced pressure. The residue was subjected to preparative TLC (SiO₂, hexane/EtOAc = 2/1, v/v) to give **13i** as major product and **13i'** as minor one in 51% (199 mg) and 45% (177 mg) yields, respectively. **13i**: mp 160.0–161.0 °C (EtOAc–hexane); [α]_D²⁵ –54.03° (*c* 0.74, EtOH); IR (KBr): 3423, 2985, 2953, 1806, 1748, 1722, 1702, 1503, 1368, 1340, 1243, 1216, 1196, 1143, 1020, 757, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.45 (s, 9H), 1.48 (d, *J* = 7.07 Hz, 3H), 3.20 (s, 3H), 5.02 (d, *J* = 8.05 Hz, 1H), 5.14 (d, *J* = 9.03 Hz, 1H), 5.40 (dq, *J* = 7.07, 8.05 Hz, 1H), 5.82 (d, *J* = 9.03 Hz, 1H), 7.28–7.44 (m, 2H), 7.36–7.44 (m, 3H). Found: C, 58.08; H, 6.14; N, 7.10%. Calcd for C₁₉H₂₄N₂O₇: C, 58.15; H, 6.17; N, 7.14%. **13i'**: mp 145.0–146.0 °C (EtOAc–hexane); [α]_D²⁵ –38.59° (*c* 0.68, EtOH); IR (KBr): 3374, 2981, 2934, 1784, 1747, 1725, 1692, 1627, 1521, 1359, 1249, 1215, 1200, 1166, 1140, 1012, 760, 701 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.42–1.50 (br, 3H), 1.44 (s, 9H), 3.24 (s, 3H), 5.03 (d, *J* = 8.78 Hz, 1H), 5.22–5.34 (br, 1H), 5.39–5.58 (br, 1H), 5.81 (d, *J* = 8.78 Hz, 1H), 7.28–7.35 (m, 2H), 7.36–7.43 (m, 3H). Found: C, 58.23; H, 6.31; N, 7.05%. Calcd for C₁₉H₂₄N₂O₇: C, 58.15; H, 6.17; N, 7.14%.

The physical and spectral data of compounds **13a–13h'** and **13j–13k'** are shown in the following.

3-(Boc-glycyl)-cis-4-methoxycarbonyl-5-methyloxazolidin-2-one (13a): Oil; IR (film): 3355, 2979, 2925, 2852, 1749, 1521, 1393, 1368, 1218, 1164, 1099, 1054, 952, 862, 761 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.42 (d, $J = 6.24$ Hz, 3H), 1.45 (s, 9H), 3.81 (s, 3H), 4.42–4.50 (m, 1H), 4.57–4.70 (m, 1H), 4.85 (d, $J = 8.62$ Hz, 1H), 4.91 (dq, $J = 6.24, 8.62$ Hz, 1H), 4.99–5.13 (br, 1H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 317.1355. Calcd for $\text{C}_{13}\text{H}_{21}\text{N}_2\text{O}_7$: 317.1349.

3-(Boc-alanyl)-cis-4-methoxycarbonyl-5-methyloxazolidin-2-one (13b and 13b'): **13b:** oil; $[\alpha]_{\text{D}}^{25} + 21.08^\circ$ (c 1.28, EtOH); IR (film): 3391, 2980, 2936, 1794, 1754, 1707, 1507, 1454, 1392, 1367, 1217, 1166, 1099, 1071, 1054, 1020, 981, 953, 862, 758 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.42 (d, $J = 6.24$ Hz, 3H), 1.43 (d, $J = 6.97$ Hz, 3H), 1.43 (s, 9H), 3.80 (s, 3H), 4.90 (d, $J = 8.80$ Hz, 1H), 4.91 (dq, $J = 6.24, 8.80$ Hz, 1H), 4.98–5.12 (br, 1H), 5.33 (dq, $J = 6.97, 8.07$ Hz, 1H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 331.1506. Calcd for $\text{C}_{14}\text{H}_{23}\text{N}_2\text{O}_7$: 331.1505. **13b':** oil; $[\alpha]_{\text{D}}^{25} - 118.63^\circ$ (c 1.08, EtOH); IR (film): 3389, 2980, 2936, 1793, 1755, 1706, 1505, 1454, 1390, 1367, 1217, 1166, 1099, 1071, 1054, 1020, 953, 862, 758 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.42 (d, $J = 6.42$ Hz, 6H), 1.44 (s, 9H), 3.81 (s, 3H), 4.80 (d, $J = 8.44$ Hz, 1H), 4.89 (dq, $J = 6.42, 8.44$ Hz, 1H), 5.20–5.34 (br, 1H), 5.36–5.52 (m, 1H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 331.1498. Calcd for $\text{C}_{14}\text{H}_{23}\text{N}_2\text{O}_7$: 331.1505.

3-(Boc-valyl)-cis-4-methoxycarbonyl-5-methyloxazolidin-2-one (13c and 13c'): **13c:** mp 101.5–102.5 $^\circ\text{C}$ (EtOAc–hexane); $[\alpha]_{\text{D}}^{25} - 70.66^\circ$ (c 1.17, EtOH); IR (KBr): 3440, 3004, 2973, 2870, 2840, 1795, 1760, 1718, 1698, 1509, 1458, 1366, 1212, 1164, 1100, 882, 795 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 0.83 (d, $J = 6.79$ Hz, 3H), 1.05 (d, $J = 6.79$ Hz, 3H), 1.41 (d, $J = 2.93$ Hz, 3H), 1.45 (s, 9H), 2.30–2.38 (m, 1H), 3.80 (s, 3H), 4.87 (dq, $J = 6.42, 8.44$ Hz, 1H), 4.90 (d, $J = 8.44$ Hz, 1H), 5.10–5.28 (br, 1H), 5.37 (dd, $J = 3.67, 9.35$ Hz, 1H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 359.1825. Calcd for $\text{C}_{16}\text{H}_{27}\text{N}_2\text{O}_7$: 359.1818. **13c':** oil; $[\alpha]_{\text{D}}^{25} + 61.48^\circ$ (c 0.96, EtOH); IR (film): 3437, 3392, 2972, 2935, 2875, 1793, 1750, 1705, 1500, 1392, 1365, 1211, 1164, 1098, 1054, 1017, 758, 667 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 0.85 (d, $J = 6.79$ Hz, 3H), 1.09 (d, $J = 6.79$ Hz, 3H), 1.40 (d, $J = 6.42$ Hz, 3H), 1.44 (s, 9H), 2.20–2.24 (br, 1H), 3.79 (s, 3H), 4.77 (d, $J = 8.44$ Hz, 1H), 4.86 (dq, $J = 6.42, 8.44$ Hz, 1H), 5.11–5.25 (br, 1H), 5.36 (dd, $J = 3.67, 9.35$ Hz, 1H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 359.1825. Calcd for $\text{C}_{16}\text{H}_{27}\text{N}_2\text{O}_7$: 359.1818.

3-(Boc-leucyl)-cis-4-methoxycarbonyl-5-methyloxazolidin-2-one (13d and 13d'): **13d:** mp 92.0–93.0 $^\circ\text{C}$ (EtOAc–hexane); $[\alpha]_{\text{D}}^{25} - 84.34^\circ$ (c 0.86, EtOH); IR (KBr): 3396, 3331, 2963, 2937, 2873, 1796, 1746, 1712, 1524, 1390, 1367, 1253, 1212, 1167, 1100, 1051, 1026, 951, 786, 759 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 0.96 (d, $J = 6.42$ Hz, 3H), 1.03 (d, $J = 6.42$ Hz, 3H), 1.40 (d, $J = 6.42$ Hz, 3H), 1.43 (s, 9H), 1.55–1.90 (m, 3H), 3.80 (s, 3H), 4.84–4.96 (m, 2H), 4.91 (d, $J = 8.80$ Hz, 1H), 5.30–5.52 (m, 1H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 373.1972. Calcd for $\text{C}_{17}\text{H}_{29}\text{N}_2\text{O}_7$: 373.1975. **13d':** oil; $[\alpha]_{\text{D}}^{25} + 31.83^\circ$ (c 0.31, EtOH); IR (film): 3352, 2960, 2872, 1793, 1756, 1708, 1507, 1456, 1439, 1366, 1212, 1168, 1098, 1051, 1024, 757, 666 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 0.93 (d, $J = 6.60$ Hz, 3H), 1.03 (d, $J = 6.24$ Hz, 3H), 1.42–1.48 (m, 1H), 1.70–1.88 (m, 3H), 3.80 (s, 3H), 4.77 (d, $J = 8.44$ Hz, 1H), 4.86 (dq, $J = 6.42, 8.44$ Hz, 1H), 5.09 (d, $J = 8.49$ Hz, 1H), 5.38–5.56 (m, 1H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 373.1977. Calcd for $\text{C}_{17}\text{H}_{29}\text{N}_2\text{O}_7$:

373.1975.

3-(Boc-glycyl)-cis-4-methoxycarbonyl-5-(2-phenylethyl)oxazolidin-2-one (13e): Oil; IR (film): 3356, 3062, 3006, 2979, 2933, 1715, 1516, 1438, 1393, 1368, 1215, 1166, 1054, 1030, 754, 701, 667 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.45 (s, 9H), 1.84–2.00 (m, 2H), 2.58–2.81 (m, 1H), 2.81–2.96 (m, 1H), 3.79 (s, 3H), 4.38–4.50 (m, 1H), 4.53–4.64 (m, 1H), 4.66 (dt, $J = 4.22, 8.44$ Hz, 1H), 4.82 (d, $J = 8.44$ Hz, 1H), 5.00–5.16 (br, 1H), 7.16–7.38 (m, 5H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 407.1814. Calcd for $\text{C}_{20}\text{H}_{27}\text{N}_2\text{O}_7$: 407.1818.

3-(Boc-alanyl)-cis-4-methoxycarbonyl-5-(2-phenylethyl)oxazolidin-2-one (13f and 13f'): **13f:** oil; $[\alpha]_{\text{D}}^{25} - 63.78^\circ$ (c 1.08, EtOH); IR (film): 3626, 3393, 3026, 3006, 2979, 2935, 1825, 1793, 1753, 1709, 1497, 1455, 1369, 1215, 1167, 1073, 1055, 1021, 757, 701 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.42 (s, 9H), 1.44 (d, $J = 6.79$ Hz, 3H), 1.80–2.00 (m, 2H), 2.65–2.85 (m, 1H), 2.85–3.00 (m, 1H), 3.77 (s, 3H), 4.66 (ddd, $J = 4.04, 8.62, 9.72$ Hz, 1H), 4.87 (d, $J = 8.62$ Hz, 1H), 4.96–5.10 (br, 1H), 5.32 (dq, $J = 6.79, 7.15$ Hz, 1H), 7.14–7.38 (m, 5H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 421.1978. Calcd for $\text{C}_{21}\text{H}_{29}\text{N}_2\text{O}_7$: 421.1975. **13f':** oil; $[\alpha]_{\text{D}}^{25} - 119.94^\circ$ (c 0.32, EtOH); IR (film): 3384, 2979, 2955, 2933, 1793, 1752, 1712, 1496, 1454, 1368, 1211, 1168, 1071, 1022, 756, 701 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.35 (d, $J = 8.83$ Hz, 3H), 1.36 (s, 9H), 1.82–2.04 (m, 2H), 2.70–2.82 (m, 1H), 2.86–2.98 (m, 1H), 3.78 (s, 3H), 4.61 (ddd, $J = 4.39, 8.29, 9.27$ Hz, 1H), 4.75 (d, $J = 8.29$ Hz, 1H), 5.15–5.30 (br, 1H), 5.40–5.50 (m, 1H), 7.15–7.36 (m, 5H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 421.1965. Calcd for $\text{C}_{21}\text{H}_{29}\text{N}_2\text{O}_7$: 421.1975.

3-(Boc-valyl)-cis-4-methoxycarbonyl-5-(2-phenylethyl)oxazolidin-2-one (13g and 13g'): **13g:** oil; $[\alpha]_{\text{D}}^{25} - 53.38^\circ$ (c 0.67, EtOH); IR (film): 3340, 2968, 2931, 1793, 1753, 1706, 1497, 1456, 1391, 1368, 1211, 1165, 1143, 1016, 756, 701 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 0.84 (d, $J = 6.79$ Hz, 3H), 1.09 (d, $J = 6.79$ Hz, 3H), 1.44 (s, 9H), 1.86–1.98 (m, 2H), 2.24–2.38 (br, 1H), 2.68–2.82 (m, 1H), 2.84–2.98 (m, 1H), 3.76 (s, 3H), 4.64 (dt, $J = 4.04, 8.80$ Hz, 1H), 4.88 (d, $J = 8.80$ Hz, 1H), 5.02 (d, $J = 9.35$ Hz, 1H), 5.36 (dd, $J = 3.67, 9.35$ Hz, 1H), 7.14–7.34 (m, 5H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 449.2281. Calcd for $\text{C}_{23}\text{H}_{33}\text{N}_2\text{O}_7$: 449.2288. **13g':** oil; $[\alpha]_{\text{D}}^{25} + 32.37^\circ$ (c 0.50, EtOH); IR (film): 3442, 3395, 3026, 2970, 2932, 2874, 1793, 1753, 1704, 1497, 1391, 1368, 1215, 1164, 1018, 756, 701 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 0.80 (d, $J = 6.79$ Hz, 3H), 1.04 (d, $J = 6.79$ Hz, 3H), 1.45 (s, 9H), 1.86–1.98 (m, 2H), 2.06–2.24 (br, 1H), 2.69–2.82 (m, 1H), 2.86–2.98 (m, 1H), 3.78 (s, 3H), 4.59 (dt, $J = 4.77, 8.62$ Hz, 1H), 4.73 (d, $J = 8.62$ Hz, 1H), 5.17 (d, $J = 9.35$ Hz, 1H), 5.44 (dd, $J = 3.76, 9.35$ Hz, 1H), 7.18–7.36 (m, 5H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 449.2274. Calcd for $\text{C}_{23}\text{H}_{33}\text{N}_2\text{O}_7$: 449.2288.

3-(Boc-glycyl)-cis-4-methoxycarbonyl-5-phenyloxazolidin-2-one (13h): Mp 118.0–119.0 $^\circ\text{C}$ (EtOAc–hexane); IR (KBr): 3397, 3025, 3008, 2978, 2955, 1794, 1742, 1732, 1697, 1523, 1394, 1381, 1338, 1270, 1249, 1233, 1195, 1168, 1143, 1051, 1018, 941, 795, 701 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.46 (s, 9H), 3.21 (s, 3H), 4.48 (dd, $J = 4.40, 19.26$ Hz, 1H), 4.71 (dd, $J = 6.79, 19.26$ Hz, 1H), 5.09 (d, $J = 8.99$ Hz, 1H), 5.04–5.12 (br, 1H), 5.82 (d, $J = 8.99$ Hz, 1H), 7.28–7.46 (m, 5H). HRMS (FAB^+) ($\text{M}^+ + 1$): Found: m/z 379.1516. Calcd for $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}_7$: 379.1505.

3-(Boc-valyl)-cis-4-methoxycarbonyl-5-phenyloxazolidin-2-one (13j and 13j'): **13j:** mp 113.5–114.5 $^\circ\text{C}$ (EtOAc–hexane); $[\alpha]_{\text{D}}^{25} - 19.66^\circ$ (c 0.44, EtOH); IR (KBr): 3416, 2968, 1796, 1748, 1710, 1510, 1456, 1370, 1343, 1217, 1163, 1134, 1053, 1020, 1001, 874, 839, 756, 697 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ

0.86 (d, $J = 6.97$ Hz, 3H), 1.13 (d, $J = 6.79$ Hz, 3H), 1.45 (s, 9H), 2.28–2.46 (br, 1H), 3.18 (s, 3H), 5.03 (d, $J = 9.36$ Hz, 1H), 5.16 (d, $J = 9.35$ Hz, 1H), 5.44 (dd, $J = 3.85, 9.36$ Hz, 1H), 5.81 (d, $J = 9.35$ Hz, 1H), 7.65–7.75 (m, 5H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 421.1989. Calcd for $C_{21}H_{29}N_2O_7$: 421.1975. **13j'**: mp 128.5–129.5 °C (EtOAc–hexane); $[\alpha]_D^{25} -12.52^\circ$ (c 0.54, EtOH); IR (KBr): 3405, 2970, 2934, 1784, 1749, 1699, 1512, 1357, 1277, 1246, 1217, 1200, 1166, 1140, 1055, 1017, 891, 758, 722, 700 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 0.86 (d, $J = 6.97$ Hz, 3H), 1.08 (d, $J = 6.79$ Hz, 3H), 1.45 (s, 9H), 2.12–2.32 (br, 1H), 3.23 (s, 3H), 5.02 (d, $J = 8.62$ Hz, 1H), 5.22 (d, $J = 9.35$ Hz, 1H), 5.44 (dd, $J = 3.85, 9.35$ Hz, 1H), 5.81 (d, $J = 8.62$ Hz, 1H), 7.28–7.44 (m, 5H). Found: C, 59.90; H, 6.79; N, 6.65%. Calcd for $C_{21}H_{28}N_2O_7$: C, 59.98; H, 6.71; N, 6.66%.

3-(Boc-leucyl)-cis-4-methoxycarbonyl-5-phenyloxazolidin-2-one (13k and 13k'): **13k**: oil; $[\alpha]_D^{25} -24.29^\circ$ (c 0.63, EtOH); IR (film): 3350, 2960, 2872, 1793, 1756, 1708, 1507, 1456, 1439, 1366, 1212, 1168, 1098, 1051, 1025, 757 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 0.98 (d, $J = 6.11$ Hz, 3H), 1.07 (d, $J = 6.05$ Hz, 3H), 1.30–1.42 (m, 1H), 1.45 (s, 9H), 1.72–1.94 (m, 2H), 3.18 (s, 3H), 4.95 (d, $J = 8.44$ Hz, 1H), 5.13 (d, $J = 9.17$ Hz, 1H), 5.40–5.54 (br, 1H), 5.82 (d, $J = 9.17$ Hz, 1H), 7.28–7.44 (m, 5H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 435.2124. Calcd for $C_{22}H_{31}N_2O_7$: 435.2121. **13k'**: oil; $[\alpha]_D^{25} -24.49^\circ$ (c 0.71, EtOH); IR (film): 3390, 2980, 2936, 1794, 1754, 1705, 1505, 1454, 1392, 1367, 1217, 1166, 1099, 758 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 0.96 (d, $J = 6.60$ Hz, 3H), 1.06 (d, $J = 6.60$ Hz, 3H), 1.44 (s, 9H), 1.38–1.52 (m, 1H), 1.55–1.67 (m, 1H), 1.75–1.92 (m, 1H), 3.24 (s, 3H), 5.01 (d, $J = 8.80$ Hz, 1H), 5.07 (m, 1H), 5.55 (ddd, $J = 3.49, 10.3, 10.4$ Hz, 1H), 5.80 (d, $J = 8.80$ Hz, 1H), 7.28–7.42 (m, 5H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 435.2135. Calcd for $C_{22}H_{31}N_2O_7$: 435.2121.

A General Procedure for Conversion of Compounds 13a–13k' to the Corresponding Dehydropeptides 14a–14k'. To a solution of **13i** (70 mg, 0.18 mmol) in dry THF (3 mL) was added 4.0 molar equivalents of LiHMDS in dry THF (2 mL) at –45 °C under N₂ and the solution was stirred for 50 min at that temperature. After the reaction was quenched with 1 M AcOH in THF at –45 °C, the solvent was removed in vacuo to give a residue, which was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc and the combined extracts were washed with brine, dried over MgSO₄, and concentrated in vacuo. The residual oil was subjected to preparative TLC (SiO₂, benzene/EtOAc = 4/1, v/v) to give methyl (*E*)-*N*-Boc-alanyldehydrophenylalaninate (**14i**) in 68% (43 mg) and methyl (*Z*)-*N*-Boc-alanyldehydrophenylalaninate (**14i'**) in 10% (6 mg) yields, respectively. (*E*)-**14i**: oil; $[\alpha]_D^{25} -2.10^\circ$ (c 0.54, EtOH); IR (film): 3317, 3057, 2979, 2932, 2853, 1718, 1680, 1644, 1493, 1367, 1267, 1167, 1114, 1068, 1020, 858, 769, 737, 692 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 1.43 (d, $J = 7.15$ Hz, 3H), 1.47 (s, 9H), 3.64 (s, 3H), 4.22–4.42 (br, 1H), 5.16 (d, $J = 7.34$ Hz, 1H), 7.16–7.34 (m, 5H), 7.69 (s, 1H), 8.38–8.64 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 349.1759. Calcd for $C_{18}H_{25}N_2O_5$: 349.1764. When the olefinic proton was irradiated, 3.9% NOE was observed for the amide NH proton. (*Z*)-**14i'**: mp 116.0–117.0 °C (EtOAc–hexane); $[\alpha]_D^{25} +66.06^\circ$ (c 0.19, EtOH); IR (KBr): 3390, 3370, 3058, 2984, 2949, 1715, 1693, 1644, 1500, 1478, 1273, 1206, 1163, 1118, 1065, 1010, 771, 694 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 1.42 (d, $J = 7.08$ Hz, 3H), 1.45 (s, 9H), 3.84 (s, 3H), 4.26–4.38 (br, 1H), 4.92–5.08 (br, 1H), 7.30–7.50 (m, 5H), 7.43 (s, 1H), 7.68–7.80 (br, 1H). Found: C, 61.88; H, 7.00; N, 7.90%. Calcd for $C_{18}H_{24}N_2O_5$: C, 62.05; H, 6.94; N, 8.04%.

In a similar way, compounds **13a–13h'** and **13j–13k'** were converted into **14a–14h'** and **14j–14k'**, whose physical and spectral data were shown in following.

Methyl 2-(Boc-glycylamino)-2-butenolate (14a and 14a'): (*E*)-**14a**: oil; IR (film): 3346, 2979, 2933, 1707, 1518, 1393, 1368, 1252, 1167, 1054, 1031, 950, 861, 757 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 1.46 (s, 9H), 2.08 (d, $J = 7.52$ Hz, 3H), 3.82–3.88 (m, 5H), 5.24–5.38 (br, 1H), 5.44 (q, $J = 7.52$ Hz, 1H), 7.98–8.12 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 273.1444. Calcd for $C_{12}H_{21}N_2O_5$: 273.1451. When the amide NH proton was irradiated, 2.0% NOE was observed for the olefinic proton. (*Z*)-**14a'**: oil (Lit. mp 100.0–101.5 °C,^{3h} 100 °C,³ⁱ and 103–104 °C²⁰). IR (film) 3321, 2979, 2959, 2932, 1721, 1514, 1439, 1368, 1281, 1168, 1073, 1052, 1029, 949, 863, 756 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 1.47 (s, 9H), 1.77 (d, $J = 7.15$ Hz, 3H), 3.76 (s, 3H), 3.92 (d, $J = 5.50$ Hz, 2H), 5.24–5.36 (br, 1H), 6.84 (q, $J = 7.15$ Hz, 1H), 7.50–7.60 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 273.1455. Calcd for $C_{12}H_{21}N_2O_5$: 273.1451.

Methyl 2-(Boc-alanylaminio)-2-butenolate (14b and 14b'): (*E*)-**14b**: mp 96.5–97.0 °C (EtOAc–hexane) (Lit. mp 100–101 °C);^{6f} $[\alpha]_D^{25} -19.83^\circ$ (c 1.10, EtOH); IR (KBr): 3319, 3047, 2982, 2955, 2935, 1738, 1677, 1662, 1531, 1367, 1345, 1254, 1167, 1116, 1070, 1043, 1026, 858, 788, 757, 715 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 1.38 (d, $J = 7.15$ Hz, 3H), 1.45 (s, 9H), 2.06 (d, $J = 8.99$ Hz, 3H), 3.82 (s, 3H), 4.35–4.60 (br, 1H), 4.90–5.15 (br, 1H), 7.17 (q, $J = 8.99$ Hz, 1H), 7.96–8.16 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 287.1600. Calcd for $C_{13}H_{23}N_2O_5$: 287.1607. When the olefinic proton was irradiated, 2.0% NOE was observed for the amide NH proton. (*Z*)-**14b'**: mp 112.0–113.0 °C (EtOAc–hexane) (Lit. Mp 114 °C,³ⁱ 115–116 °C,^{6f} and 116 °C²¹); $[\alpha]_D^{25} -18.66^\circ$ (c 0.42, EtOH); IR (KBr): 3336, 3292, 2980, 2948, 1720, 1673, 1524, 1323, 1281, 1166, 1050, 772, 705, 673 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 1.42 (d, $J = 6.97$ Hz, 3H), 1.46 (s, 9H), 1.76 (d, $J = 7.15$ Hz, 3H), 3.76 (s, 3H), 4.20–4.38 (br, 1H), 4.90–5.10 (br, 1H), 6.82 (q, $J = 7.15$ Hz, 1H), 7.46–7.58 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 287.1610. Calcd for $C_{13}H_{23}N_2O_5$: 287.1607.

Methyl 2-(Boc-valylaminio)-2-butenolate (14c and 14c'): (*E*)-**14c**: mp 133.5–134.0 °C (EtOAc–hexane); $[\alpha]_D^{25} -5.20^\circ$ (c 1.29, EtOH); IR (KBr): 3330, 3276, 3022, 2976, 2955, 2871, 1735, 1685, 1666, 1523, 1434, 1369, 1353, 1248, 1172, 1045, 1021, 1000, 930, 880, 830, 808 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 0.93 (d, $J = 6.79$ Hz, 3H), 0.98 (d, $J = 6.79$ Hz, 3H), 1.45 (s, 9H), 2.18–2.25 (m, 1H), 2.19 (d, $J = 7.52$ Hz, 3H), 3.84 (s, 3H), 3.90–4.04 (br, 1H), 4.90–5.12 (br, 1H), 7.20 (q, $J = 7.70$ Hz, 1H), 7.75–7.85 (br, 1H). Found: C, 57.10; H, 8.35; N, 8.89%. Calcd for $C_{15}H_{26}N_2O_5$: C, 57.31; H, 8.34; N, 8.91%. When the olefinic proton was irradiated, 1.1% NOE was observed for the amide NH proton. (*Z*)-**14c'**: mp 99.5–100.5 °C (EtOAc–hexane); $[\alpha]_D^{25} -11.51^\circ$ (c 0.66, EtOH); IR (KBr): 3326, 3284, 2955, 2871, 1732, 1685, 1660, 1525, 1508, 1300, 1278, 1247, 1169, 1070, 1045, 932, 876, 806 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 0.98 (d, $J = 6.79$ Hz, 3H), 1.03 (d, $J = 6.79$ Hz, 3H), 1.17 (d, $J = 7.34$ Hz, 3H), 1.45 (s, 9H), 2.14–2.32 (m, 1H), 3.76 (s, 3H), 4.00–4.10 (m, 1H), 4.96–5.14 (br, 1H), 6.83 (q, $J = 7.15$ Hz, 1H), 7.26–7.35 (br, 1H). Found: C, 57.31; H, 8.45; N, 8.87%. Calcd for $C_{15}H_{26}N_2O_5$: C, 57.31; H, 8.34; N, 8.91%.

Methyl 2-(Boc-leucylaminio)-2-butenolate (14d and 14d'): (*E*)-**14d**: mp 93.5–94.5 °C (EtOAc–hexane); $[\alpha]_D^{25} -20.08^\circ$ (c 0.91, EtOH); IR (KBr): 3281, 3052, 2976, 2925, 2872, 1727, 1664, 1536, 1366, 1352, 1292, 1257, 1166, 1047, 1023, 850, 785 cm^{-1} ; ¹H NMR (300 MHz, CDCl₃): δ 0.94 (d, $J = 6.23$ Hz, 3H), 0.96 (d,

$J = 6.42$ Hz, 3H), 1.45 (s, 9H), 1.46–1.52 (m, 1H), 1.66–1.78 (m, 2H), 2.09 (d, $J = 7.70$ Hz, 3H), 3.83 (s, 3H), 4.06–4.22 (br, 1H), 4.76–4.96 (br, 1H), 7.20 (q, $J = 7.70$ Hz, 1H), 7.90–8.10 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 329.1984. Calcd for C₁₆H₂₉N₂O₅: 329.2077. When the olefinic proton was irradiated, 2.1% NOE was observed for the amide NH proton. (*Z*)-**14d'**: oil; $[\alpha]_D^{25} + 71.63^\circ$ (c 0.20, EtOH); IR (neat): 3348, 2979, 2932, 2853, 1710, 1521, 1454, 1393, 1368, 1280, 1252, 1167, 1054, 950, 861, 760 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.95 (d, $J = 6.05$ Hz, 3H), 0.96 (d, $J = 6.41$ Hz, 3H), 1.46 (s, 9H), 1.55–1.80 (m, 6H), 3.76 (s, 3H), 4.05–4.30 (br, 1H), 4.80–5.00 (br, 1H), 6.81 (q, $J = 7.15$ Hz, 1H), 7.46–7.58 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 329.2079. Calcd for C₁₆H₂₉N₂O₅: 329.2077.

Methyl 2-(Boc-glycylamino)-5-phenyl-2-pentenoate (14e and 14e'): (*E*)-**14e**: oil; IR (film): 3326, 2978, 2928, 2849, 1715, 1681, 1520, 1455, 1367, 1249, 1165, 1066, 751, 700 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.46 (s, 9H), 2.77 (t, $J = 7.34$ Hz, 2H), 2.82–2.93 (m, 2H), 3.80 (s, 3H), 3.86 (d, $J = 5.87$ Hz, 2H), 5.10–5.24 (br, 1H), 7.16–7.34 (m, 6H), 8.00–8.10 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 363.1929. Calcd for C₁₉H₂₇N₂O₅: 363.1920. When the methylene protons at γ -protons were irradiated, 1.1% NOE was observed for the methyl ester protons. (*Z*)-**14e'**: oil; IR (film): 3316, 2979, 2933, 1712, 1518, 1454, 1367, 1248, 1167, 1066, 859, 755, 700 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.45 (s, 9H), 2.47 (dt, $J = 7.32$, 7.56 Hz, 2H), 2.78 (t, $J = 7.56$ Hz, 2H), 3.75 (s, 3H), 3.87 (d, $J = 5.87$ Hz, 2H), 5.09–5.22 (br, 1H), 6.73 (t, $J = 7.32$ Hz, 1H), 7.15–7.35 (m, 6H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 363.1920. Calcd for C₁₉H₂₇N₂O₅: 363.1920.

Methyl 2-(Boc-alanyl-amino)-5-phenyl-2-pentenoate (14f and 14f'): (*E*)-**14f**: oil; $[\alpha]_D^{25} - 22.10^\circ$ (c 0.17, EtOH); IR (film): 3311, 2978, 2932, 1684, 1605, 1521, 1454, 1366, 1249, 1167, 1066, 1021, 749, 699 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.38 (d, $J = 7.15$ Hz, 3H), 1.45 (s, 9H), 2.72–2.84 (m, 2H), 2.84–2.96 (m, 2H), 3.80 (s, 3H), 4.14–4.28 (br, 1H), 4.90–5.08 (br, 1H), 7.14–7.32 (m, 6H), 8.06–8.16 (br, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 377.2082. Calcd for C₂₀H₂₉N₂O₅: 377.2077. (*Z*)-**14f'**: oil; $[\alpha]_D^{25} - 1.95^\circ$ (c 0.44, EtOH); IR (film): 3299, 2979, 2931, 1790, 1684, 1650, 1498, 1366, 1269, 1249, 1164, 1065, 1023, 746, 699 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.38 (d, $J = 7.15$ Hz, 3H), 1.44 (s, 9H), 2.46 (q, $J = 7.52$ Hz, 2H), 2.78 (t, $J = 7.52$ Hz, 2H), 3.75 (s, 3H), 4.16–4.30 (br, 1H), 4.89–4.96 (br, 1H), 6.71 (t, $J = 7.33$ Hz, 1H), 7.16–7.36 (m, 6H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 377.2088. Calcd for C₂₀H₂₉N₂O₅: 377.2077.

Methyl 2-(Boc-valyl-amino)-5-phenyl-2-pentenoate (14g and 14g'): (*E*)-**14g**: mp 114.0–115.0 °C (EtOAc–hexane); $[\alpha]_D^{25} + 3.55^\circ$ (c 0.22, EtOH); IR (KBr): 3329, 3298, 3031, 2981, 2964, 2932, 2873, 1729, 1687, 1666, 1652, 1603, 1526, 1518, 1386, 1300, 1246, 1174, 1010, 744, 698 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.93 (d, $J = 6.79$ Hz, 3H), 0.99 (d, $J = 6.79$ Hz, 3H), 1.45 (s, 9H), 2.14–2.25 (m, 1H), 2.73–2.84 (m, 2H), 2.81–2.93 (m, 2H), 3.79 (s, 3H), 3.90–4.06 (br, 1H), 4.98–5.14 (br, 1H), 7.14 (t, $J = 7.70$ Hz, 1H), 7.18–7.32 (m, 5H), 7.88 (br s, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 405.2387. Calcd for C₂₂H₃₃N₂O₅: 405.2390. When the γ -methylene protons were irradiated, 1.7% NOE was observed for protons of the methyl ester. (*Z*)-**14g'**: mp 99.0–100.0 °C (EtOAc–hexane); $[\alpha]_D^{25} + 14.86^\circ$ (c 0.07, EtOH); IR (KBr): 3331, 3293, 3018, 2965, 2839, 1732, 1723, 1685, 1662, 1524, 1507, 1294, 1169, 750, 699 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.94 (d, $J = 6.79$ Hz, 3H), 1.00 (d, $J = 6.79$ Hz, 3H), 1.43 (s, 9H), 2.15–2.24 (m, 1H), 2.48 (q, $J = 7.34$ Hz, 2H), 2.79 (t, $J = 7.34$ Hz, 2H), 3.75 (s, 3H), 3.97 (dd, $J = 6.05$, 8.07 Hz, 1H),

4.92–5.10 (br, 1H), 6.72 (t, $J = 7.34$ Hz, 1H), 7.06 (br s, 1H), 7.16–7.34 (m, 5H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 405.2396. Calcd for C₂₂H₃₃N₂O₅: 405.2390.

Methyl *N*-Boc-glycyldehydrophenylalaninate (14h and 14h'): (*E*)-**14h**: mp 130.5–131.5 °C (EtOAc–hexane); IR (KBr): 3286, 3240, 2979, 2940, 1747, 1698, 1636, 1539, 1439, 1364, 1299, 1252, 1219, 1166, 982, 942, 760, 705 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.48 (s, 9H), 3.64 (s, 3H), 3.92 (d, $J = 5.87$ Hz, 2H), 5.34 (t, $J = 5.89$ Hz, 1H), 7.20–7.36 (m, 5H), 7.81 (s, 1H), 8.37 (br s, 1H). Found: C, 60.82; H, 6.59; N, 8.36%. Calcd for C₁₇H₂₂N₂O₅: C, 61.06; H, 6.63; N, 8.38%. When the amide NH proton was irradiated, 6.6% NOE was observed for the olefinic proton. (*Z*)-**14h'**: oil (Lit. mp 62.5–64 °C);^{3h} IR (film): 3299, 2979, 2951, 2933, 1686, 1638, 1521, 1367, 1252, 1165, 1052, 1030, 865, 754, 697 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.45 (s, 9H), 3.84 (s, 3H), 3.92 (d, $J = 5.14$ Hz, 2H), 5.16–5.28 (br, 1H), 7.31–7.52 (m, 5H), 7.44 (s, 1H), 7.69 (br s, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 335.1614. Calcd for C₁₇H₂₃N₂O₅: 335.1607.

Methyl *N*-Boc-valyldehydrophenylalaninate (14j and 14j'): (*E*)-**14j**: mp 143.5–144.5 °C (EtOAc–hexane); $[\alpha]_D^{25} + 22.81^\circ$ (c 1.11, EtOH); IR (KBr): 3287, 3050, 3040, 2972, 2880, 1734, 1678, 1661, 1532, 1392, 1367, 1299, 1252, 1222, 1167, 1045, 1021, 750, 697 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.98 (d, $J = 6.83$ Hz, 3H), 1.03 (d, $J = 6.59$ Hz, 3H), 1.45 (s, 9H), 2.18–2.32 (m, 1H), 3.64 (s, 3H), 3.98–4.14 (br, 1H), 4.96–5.18 (br, 1H), 7.20–7.34 (m, 5H), 7.76 (s, 1H), 8.16 (br s, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 377.2068. Calcd for C₂₀H₂₉N₂O₅: 377.2077. When the olefinic proton was irradiated, 2.5% NOE was observed for the amide NH proton. (*Z*)-**14j'**: mp 146.0–147.0 °C (EtOAc–hexane); $[\alpha]_D^{25} + 45.37^\circ$ (c 0.15, EtOH); IR (KBr): 3323, 3247, 3010, 2959, 2930, 2879, 1729, 1687, 1665, 1526, 1366, 1300, 1275, 1249, 1202, 1172, 762, 681 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.97 (d, $J = 6.79$ Hz, 3H), 1.03 (d, $J = 6.79$ Hz, 3H), 1.46 (s, 9H), 2.18–2.34 (m, 1H), 3.84 (s, 3H), 4.05 (dd, $J = 5.87$, 8.62 Hz, 1H), 4.92–5.10 (br, 1H), 7.30–7.38 (m, 3H), 7.40 (s, 1H), 7.48 (d, $J = 6.42$ Hz, 2H), 7.54 (br s, 1H). Found: C, 63.77; H, 7.58; N, 7.28%. Calcd for C₂₀H₂₈N₂O₅: C, 63.81; H, 7.50; N, 7.44%.

Methyl *N*-Boc-leucyldehydrophenylalaninate (14k and 14k'): (*E*)-**14k**: mp 151.5–152.5 °C (EtOAc–hexane); $[\alpha]_D^{25} + 13.71^\circ$ (c 0.18, EtOH); IR (KBr): 3276, 3051, 2953, 2870, 1738, 1670, 1636, 1541, 1436, 1397, 1368, 1318, 1297, 1254, 1221, 1171, 1052, 1030, 982, 758, 696 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.96 (d, $J = 6.05$ Hz, 3H), 0.98 (d, $J = 6.41$ Hz, 3H), 1.47 (s, 9H), 1.49–1.62 (m, 1H), 1.67–1.84 (m, 2H), 3.64 (s, 3H), 4.14–4.32 (br, 1H), 4.90 (d, $J = 7.32$ Hz, 1H), 7.20–7.34 (m, 5H), 7.79 (s, 1H), 8.35 (br s, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 391.2231. Calcd for C₂₁H₃₁N₂O₅: 391.2233. When the olefinic proton was irradiated, 4.0% NOE was observed for the amide NH proton. (*Z*)-**14k'**: oil; $[\alpha]_D^{25} + 10.31^\circ$ (c 0.30, EtOH); IR (film): 3299, 2957, 2940, 2870, 1690, 1512, 1267, 1168, 918, 732, 692 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.94 (d, $J = 6.10$ Hz, 3H), 0.97 (d, $J = 6.34$ Hz, 3H), 1.46 (s, 9H), 1.48–1.52 (m, 1H), 1.67–1.84 (m, 2H), 3.82 (s, 3H), 4.18–4.32 (br, 1H), 4.92 (d, $J = 8.05$ Hz, 1H), 7.26–7.38 (m, 3H), 7.40 (s, 1H), 7.48 (d, $J = 7.07$ Hz, 2H), 7.77 (br s, 1H). HRMS (FAB⁺) ($M^+ + 1$): Found: m/z 391.2236. Calcd for C₂₁H₃₁N₂O₅: 391.2233.

4-(*N*-Z-amino)-1-butyl Acetate (15). To a mixture of 4-amino-1-butanol (1.782 g, 20 mmol) and sodium carbonate (2.332 g, 22 mmol) in water (46 mL) was added dropwise a solution of Z-Cl (3.410 g, 20 mmol) in THF (40 mL) at 0 °C. The mixture was allowed to stand overnight at room temperature and

the THF was removed in vacuo to give a residue, which was partitioned between EtOAc and water. The EtOAc solution was washed with brine, dried, and evaporated in vacuo to afford the product in quantitative yield (4.46 g).

To a solution of the resulting alcohol (4.46 g, 20 mmol) in THF (20 mL) was added a catalytic amount of DMAP followed by the addition of acetic anhydride (3.77 mL, 40 mmol) at room temperature. After stirring for 20 min, the reaction was quenched with a saturated solution of aqueous NaHCO₃ and the solvent was removed in vacuo. The residue was dissolved in EtOAc and the organic solution was washed with brine, dried over MgSO₄, and evaporated under reduced pressure to afford the desired product **15** in 94% yield (4.98 g). Oil; IR (neat): 3344, 3033, 2951, 1723, 1603, 1530, 1455, 1366, 1247, 1138, 1038, 993, 741, 698 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.53–1.66 (m, 4H), 2.02 (s, 3H), 3.17–3.23 (m, 2H), 4.03–4.14 (m, 2H), 5.07 (s, 2H), 5.08 (br, 1H), 7.33 (br, 5H). HRMS (FAB⁺) (M⁺ + 1): Found: *m/z* 266.1393. Calcd for C₁₄H₂₀NO₄: 266.1392.

4-(N-Boc-N-Z-amino)-1-butyl Acetate (16). To a solution of **15** (4.98 g, 18.7 mmol) in dry THF (15 mL) was added a solution of a catalytic amount of DMAP in dry THF (5 mL) at 0 °C followed by the addition of a solution of Boc₂O (6.22 g, 28.5 mmol) in dry THF at that temperature. The solution was allowed to stand overnight at room temperature. After evaporation of the solvent, the residue was partitioned between EtOAc and water. The organic solution was washed with brine, dried over MgSO₄, and concentrated under reduced pressure to give compound **16** in 81% yield (5.58 g). Oil; IR (neat): 2978, 1792, 1739, 1697, 1609, 1587, 1550, 1498, 1475, 1369, 1290, 1240, 1202, 1100, 1072, 852, 780, 753, 700 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.47 (s, 9H), 1.61–1.66 (br, 4H), 2.02 (s, 3H), 3.67 (t, *J* = 6.83 Hz, 2H), 4.04 (t, *J* = 6.10 Hz, 2H), 5.22 (s, 2H), 7.32–7.40 (m, 5H). HRMS (FAB⁺) (M⁺ + 1): Found: *m/z* 366.1916. Calcd for C₁₉H₂₈NO₆: 366.1916.

4-(N-Boc-N-Z-amino)-1-butanol (17). Compound **16** (1.120 g, 3.07 mmol) was dissolved in 0.5 M HCl in MeOH (63 mL) at 0 °C. The solution was gradually warmed to room temperature and allowed to stand overnight. After neutralization with a saturated solution of NaHCO₃ at 0 °C, the MeOH was removed in vacuo to afford a residue, which was extracted with EtOAc. The EtOAc solution was washed with brine, dried over MgSO₄, and evaporated in vacuo to give a residue, which was subjected to silica gel column chromatography (eluent; hexane/EtOAc = 1/1, v/v) giving the product **17** (765 mg, 77%). Oil; IR (neat): 3487, 2977, 2938, 2870, 1782, 1736, 1455, 1369, 1294, 1253, 1119, 1065, 1030, 751 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.47 (s, 9H), 1.51–1.68 (m, 4H), 2.02 (br, 1H), 3.59–3.69 (m, 4H), 5.21 (s, 2H), 7.31–7.38 (m, 5H). HRMS (FAB⁺) (M⁺ + 1): Found: *m/z* 324.1811. Calcd for C₁₇H₂₆NO₅: 324.1811.

Isomerization of the (E)-N-Boc-α,β-didehydroamino Acid Methyl Ester **1 to the Corresponding Z Isomer **1'** by Iodine.** To a solution of **1a** (41 mg, 0.19 mmol) in dry THF (2 mL) was added a catalytic amount of iodine at room temperature under N₂. The solution was stirred for 19 h at that temperature and quenched with a saturated solution of NaHSO₃. The solvent was removed in vacuo to afford the residue, which was extracted with EtOAc. The organic solution was washed with brine, dried over MgSO₄, and concentrated in vacuo to give a residue, which was subjected to preparative TLC (SiO₂, hexane/EtOAc = 4/1, v/v) to afford Z isomer, **1a'** (35 mg) and E isomer, **1a** (<2 mg).

Compounds **1b–1h** were isomerized to their Z isomers in the same way. The results are summarized in Table 7.

References

- 1 a) T. Ueno, T. Nakashima, Y. Hayashi, H. Fukami, *Agric. Biol. Chem.* **1975**, *39*, 1115. b) R. D. Durbin, *Toxins in Plant Disease*, Physiological Ecology Series, Academic Press, **1981**, p. 357. c) T. Shiroza, N. Ebisawa, A. Kojima, K. Furihata, A. Shimazu, T. Endo, H. Seto, N. Otake, *Agric. Biol. Chem.* **1982**, *46*, 1885. d) D. P. Botes, A. A. Tuinman, P. L. Wessels, C. C. Viljoen, H. Kruger, D. H. Williams, S. Santikarn, R. J. Smith, S. J. Hammond, *J. Chem. Soc., Perkin Trans. 1* **1984**, 2311. e) M. F. Mackay, A. Van Donkelaar, C. C. J. Culvenor, *J. Chem. Soc., Chem. Commun.* **1986**, 1219. f) K. Nagaoka, M. Matsumoto, J. Oono, K. Yokoi, S. Ishizeki, T. Nakashima, *J. Antibiot.* **1986**, *36*, 1527. g) K. L. Rinehart, K. Harada, M. Namikoshi, C. Chen, C. A. Harvis, M. H. G. Munro, J. W. Blunt, P. E. Mulligan, Y. R. Beasley, A. M. Dahlem, W. W. Carmichael, *J. Am. Chem. Soc.* **1988**, *110*, 8557. h) E. D. de Silva, D. E. Williams, R. J. Anderson, H. Klix, C. F. B. Holmes, T. M. Allen, *Tetrahedron Lett.* **1992**, *33*, 1561.
- 2 a) Y. Shimohigashi, N. Izumiya, *J. Synth. Org. Chem., Jpn.* **1978**, *36*, 1023. b) C. Shin, *J. Synth. Org. Chem., Jpn.* **1979**, *37*, 830. c) G. H. Fisher, P. Berryer, J. W. Ryan, V. Chauhan, C. H. Stammer, *Arch. Biochem. Biophys.* **1981**, *211*, 269. d) K. Nunami, M. Suzuki, N. Yoneda, *Chem. Pharm. Bull.* **1982**, *30*, 4015. e) T. Wakamiya, K. Shimbo, A. Sano, K. Fukase, H. Yasuda, T. Shiba, *Pept. Chem.* **1982**, *1983*, 149. f) Y. Shimohigashi, C. H. Stammer, *J. Chem. Soc., Perkin Trans. 1* **1983**, 803. g) R. Jacquier, J. Verducci, *Tetrahedron Lett.* **1984**, *25*, 2775. h) S. F. Brady, D. W. Cochran, R. F. Nutt, F. W. Holly, C. D. Bernnett, W. J. Paleveda, P. E. Curley, B. H. Arison, R. Saperstein, D. F. Veber, *Int. Pept. Protein Res.* **1984**, *23*, 212.
- 3 a) I. Photaki, *J. Am. Chem. Soc.* **1963**, *85*, 1123. b) D. H. Rich, J. Tam, *J. Org. Chem.* **1977**, *42*, 3815. c) D. H. Rich, J. Tam, P. Mathiaraman, J. A. Grant, C. Mabuni, *J. Chem. Soc., Chem. Commun.* **1974**, 897. d) C. Shin, Y. Yonezawa, K. Unoki, J. Yoshimura, *Tetrahedron Lett.* **1979**, *20*, 1049. e) S. Nomoto, A. Sano, T. Shiba, *Tetrahedron Lett.* **1979**, *20*, 521. f) P. A. Manis, M. W. Rathke, *J. Org. Chem.* **1980**, *45*, 4952. g) U. Schmidt, A. Lieberknecht, J. Wild, *Synthesis* **1984**, 53. h) P. M. T. Ferreira, L. S. Monteiro, G. Pereira, L. Ribeiro, J. Sacramento, L. Silva, *Eur. J. Org. Chem.* **2007**, 5934. i) R. Ramesh, K. De, S. Chandrasekaran, *Tetrahedron* **2007**, *63*, 10534.
- 4 T. Nagano, H. Kinoshita, *Bull. Chem. Soc. Jpn.* **2000**, *73*, 1605.
- 5 R. Kimura, T. Nagano, H. Kinoshita, *Bull. Chem. Soc. Jpn.* **2002**, *75*, 2517.
- 6 a) A. Srinivasan, R. W. Stephenson, R. K. Olsen, *J. Org. Chem.* **1977**, *42*, 2253. b) L. Somekh, A. Shanzer, *J. Org. Chem.* **1983**, *48*, 907. c) M. M. Stohlmeyer, H. Tanaka, T. J. Wandless, *J. Am. Chem. Soc.* **1999**, *121*, 6100. d) N. O. Silva, A. S. Abreu, P. M. T. Ferreira, L. S. Monteiro, M.-J. R. P. Queiroz, *Eur. J. Org. Chem.* **2002**, 2524. e) F. Yokokawa, T. Shioiri, *Tetrahedron Lett.* **2002**, *43*, 8679. f) H. Sai, T. Ogiku, H. Ohmizu, *Synthesis* **2003**, 201.
- 7 R. Jumnah, J. M. J. Williams, A. C. Williams, *Tetrahedron Lett.* **1993**, *34*, 6619.
- 8 a) Y. Yonezawa, T. Obara, C. Shin, *Nippon Kagaku Kaishi* **1987**, 838. b) H. Poisel, *Chem. Ber.* **1977**, *110*, 942; **1977**, *110*, 948. c) H.-J. Kreuzfeld, C. Döbler, H. W. Krause, C. Facklam, *Tetrahedron: Asymmetry* **1993**, *4*, 2047.
- 9 a) O. Miyata, H. Asai, T. Naito, *Chem. Pharm. Bull.* **2005**, *53*, 355. b) D. Crich, A. Banerjee, *J. Org. Chem.* **2006**, *71*, 7106.

- 10 T. Kawabata, H. Suzuki, Y. Nagae, K. Fujii, *Angew. Chem., Int. Ed.* **2000**, *39*, 2155.
- 11 a) A. Shanzer, L. Somekh, D. Butina, *J. Org. Chem.* **1979**, *44*, 3967. b) U. Schmidt, W. Siegel, *Tetrahedron Lett.* **1987**, *28*, 2849.
- 12 Y. Shiraishi, H. Yamauchi, T. Takamura, H. Kinoshita, *Bull. Chem. Soc. Jpn.* **2004**, *77*, 2219.
- 13 P. A. Alexander, S. P. Marsden, D. M. M. Subtil, J. C. Reader, *Org. Lett.* **2005**, *7*, 5433.
- 14 H.-J. Kreuzfeld, U. Schmidt, C. Döbler, H. W. Krause, *Tetrahedron: Asymmetry* **1996**, *7*, 1011.
- 15 E. Tullberg, D. Peters, T. Frejd, *J. Organomet. Chem.* **2004**, *689*, 3778.
- 16 L.-X. Liao, W.-S. Zhou, *Tetrahedron* **1998**, *54*, 12571.
- 17 D. L. Preuss, M. Kellett, *J. Antibiot.* **1983**, *36*, 213.
- 18 J. M. Jiménez, J. Rifé, R. M. Ortúño, *Tetrahedron: Asymmetry* **1995**, *6*, 1849.
- 19 U. Schmidt, R. Meyer, V. Leitenberger, F. Stäbler, A. Lieberknecht, *Synthesis* **1991**, 409.
- 20 C. Shin, Y. Yonezawa, M. Ikeda, *Bull. Chem. Soc. Jpn.* **1986**, *59*, 3573.
- 21 a) X. Fang, U. K. Bandarage, T. Wang, J. D. Schroeder, D. S. Garvey, *J. Org. Chem.* **2001**, *66*, 4019. b) M. F. Semmelhack, Y. Jiang, D. Ho, *Org. Lett.* **2001**, *3*, 2403.